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ABSTRACT 
 
Much of the morbidity and mortality associated with diabetes mellitus (DM) 
reflects its deleterious effect on micro- and macro-circulation. DM impairs 
physiological angiogenesis, leading to long-term complications, by molecular 
mechanisms that are not fully understood. The generation of Advanced 
Glycation End-products (AGEs) has an important role in the development of 
hyperglycemia-induced endothelial damage. Moreover, previous evidence 
demonstrated that exposure of endothelial cells to hyperglycemia induces 
sustained activation of the transcription factor nuclear-κB (NF-κB), at least in 
part by the AGEs/RAGE pathways, leading to accelerated vascular disease.  
One of the main precursors of AGEs in endothelial cells is Methylglyoxal 
(MGO), a highly reactive dycarbonyl detoxified by the Glyoxalase System, of 
which Glyoxalase 1 (Glo1) is the rate limiting enzyme. 
In this study, we aim at evaluating the effect of MGO on the angiogenic ability 
of aortic endothelial cells isolated from Glo1 knock-down mice (Glo1KD 
MAECs) and their WT littermates (WT MAECs).  
Glo1KD MAECs show a reduced expression of Glo1 that is paralleled to an 
increase of MGO accumulation. This leads to an impairment of angiogenic 
ability of Glo1KD MAECs characterized by a reduced proliferation, migration 
and invasion. 
Both protein and mRNA levels of the antiangiogenic HoxA5 gene are increased 
in Glo1KD MAECs compared to WT MAECs. Interestingly, HoxA5 silencing, 
is able to improve migration and invasion of Glo1KD MAECs.  
Moreover, MGO accumulation in Glo1KD MAECs causes the overexpression 
of NF-κB-p65 that is also associated to a higher cytoplasmic and nuclear protein 
levels. Interestingly, there is an increased binding of NF-κB-p65 to HoxA5 
promoter in Glo1KD MAECs compared to WT MAECs, and NF-κB inhibition 
results in the reduction of HoxA5 expression. 
This study demonstrates that, through NF-κB-p65 activation, high levels of 
MGO impair angiogenic ability of MAECs via a mechanism involving the 
antiangiogenic factor HoxA5. Further investigations will allow to identify new 
strategies for the prevention and treatment of microvascular complications 
associated to diabetes. 
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1. BACKGROUND 
 
1.1 Endothelium and vascular function. 
 
Endothelium is a monolayer of cells covering the internal lumen of all the 
vasculature. For many years, this cell layer has been thought to be relatively 
inert, a mere physical barrier between circulating blood and the underlying 
tissues. However, it has now been recognized that endothelium is a complex 
organ constituted by metabolically active endothelial cells (ECs) with important 
paracrine, endocrine and autocrine functions, necessary for the maintenance of 
vascular homeostasis (Vallance 2001, Bonetti, Lerman et al. 2003, Hadi and 
Suwaidi 2007, Sena, Pereira et al. 2013). 
ECs are covered by a glycocalyx that contributes to the selectivity of their barrier 
function (van Haaren, VanBavel et al. 2003), and serves as an interface between 
circulating blood and vascular smooth muscle cells (VSMCs) wherewith 
interact, as well as cells within the blood compartment, facilitating a complex 
array of functions (De Meyer and Herman 1997, Mombouli 1997) (Figure 1). 
 
 
 
Figure 1. Vessel structure.  
 
 
Indeed, the endothelium is responsible of the regulation of vessel integrity, 
vascular growth and remodeling, as well as, tissue growth and metabolism; it 
mediates the immune responses, cell adhesion, hemostasis, vascular 
permeability. Moreover, it plays a pivotal role in the regulation of vascular tone, 
controlling tissue blood flow, inflammatory responses and maintaining blood 
fluidity (Feletou and Vanhoutte 2006, Moncada and Higgs 2006). Finally, the 
endothelium has a pivotal role in the process of angiogenesis, occurring during 
development, growth, tissue repair, but also in capillary tissue perfusion. In 
several pathological conditions, an improper angiogenic response causes 
7 
 
unwanted growth, risk for local haemorrhage by immature vessels, or 
insufficient blood supply (Carmeliet 2005) (Figure 2). 
 
 
 
Figure 2. Physiological functions of endothelium. Endothelium guarantees vascular 
homeostasis through the regulation of several biological processes that are summarized by 
rectangles in figure. (Sena, Pereira et al. 2013) 
 
 
ECs guarantee the regulation of all these functions through the production of a 
wide range of factors. Indeed, they produce endothelium-derived 
hyperpolarization factor (EDHF), nitric oxide (NO) (Ignarro, Buga et al. 1987, 
Palmer, Ferrige et al. 1987) and prostacyclin (PGI2) that exert vasodilatory and 
antiproliferative effects, while endothelin-1 (ET-1) (Yanagisawa, Kurihara et al. 
1988), angiotensin II and reactive oxygen species (ROSs) are mediators exerting 
vasoconstrictor effects (Endemann and Schiffrin 2004, Just, Whitten et al. 2008). 
ECs also produce anti-thrombotic (NO and PGI2) and pro-thrombotic molecules, 
such as vonWillebrand factor (vWF) and plasminogen activator inhibitor-1 
(PAI-1), which promotes platelet aggregation and inhibits fibrinolysis, 
respectively (Moncada and Higgs 2006). 
In this way, the endothelium maintains the balance between vasodilation (NO) 
and vasoconstriction (ET-1), inhibition and promotion of migration and 
proliferation of VSMCs (NO, angiotensin II, ROSs), fibrinolysis and 
thrombogenesis as well as prevention and stimulation of platelets adhesion and 
aggregation (Moncada and Higgs 2006). Inflammatory activation of the 
endothelium can be caused by bacterial lipopolysaccaride and inflammatory 
cytokines exposure, of which the potent inducers interleukin-1 (IL-1) and tumor 
necrosis factor-α (TNFα) have drawn major attention. Inflammatory activation 
can also be induced by reactive oxygen intermediates (ROIs), which can be 
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generated by the inflammation process itself and by disturbed metabolic 
conditions, like diabetes (Gimbrone 1999). Therefore, alterations of this tightly 
regulated equilibrium leads to dysfunction of endothelial cells (Figure 3) (Sena, 
Pereira et al. 2013). 
 
 
 
Figure 3. Molecules released by endothelial cells and their role in vascular function. ACh, 
acetylcholine; ATR, angiotensin-II receptor; BK, bradykinin; EDHF, endothelium-derived 
hyperpolarization factor; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PGH2, 
prostaglandin H2; PGI2, prostacyclin; O2•−, superoxide anion; t-PA, tissue plasminogen 
activator; TM, thrombomodulin; TxA2, thromboxane A2; vWF, vonWillebrand factor. (Sena, 
Pereira et al. 2013) 
 
 
1.1.1 Angiogenesis. 
 
Among the functions exerted by endothelium, angiogenesis is one of the most 
important. Angiogenesis is a global term which indicates the new blood vessel 
formation from pre-existing ones and it is distinguished from vasculogenesis, 
which is de novo vessel formation from hematopoietic progenitor cells (Nyberg, 
Xie et al. 2005, Xu, Kanasaki et al. 2012). It is a multistep process that generally 
begins when endothelial cells switch from “quiescent” to “angiogenic” 
phenotype in response to angiogenic stimuli (Bastaki, Nelli et al. 1997, Ribatti, 
Nico et al. 2009, Neve, Cantatore et al. 2014).   
Angiogenesis is a vital process for embryological growth, tissue development, 
reproduction and wound healing in damaged tissues. Under these conditions, it 
is a highly regulated process, i.e. turned on for brief periods and then completely 
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inhibited (Folkman and Shing 1992). Indeed, in humans or vertebrates, normal 
vascularization is quiescent, suggesting that in vivo there are anti-angiogenic 
factors that act against angiogenic factors. Among the endogenous anti-
angiogenic factors, the most important include thrombospondins (TSPs), 
angiostatin and endostatin (Huang and Bao 2004). 
Angiogenesis requires extensive interaction between a variety of cells and 
molecules and it is controlled by several peptides and other modulating factors. 
In order for vascular sprouting to occur, a cascade of events have to be completed 
(Tomanek and Schatteman 2000).  
First, enzymatic degradation of capillary basement membrane (BM) occurs and 
vascular permeability increases leading to extravasation of blood proteins and 
their accumulation into interstitial collagen matrix to form a new, provisional 
extracellular matrix (ECM). Then, endothelial cells begin to proliferate, invade 
the ECM, and take part in the formation of an immature capillary structure and 
deposition of a new complex BM. Finally, pericytes are recruited, thereby 
providing stabilization for the new vessel. The soluble growth factors, 
membrane-bound proteins, cell-matrix and cell-cell interactions, together with 
hemodynamic forces all act in concert to control and influence angiogenesis. The 
balanced activity between specific angiogenic molecules which can initiate this 
process and specific inhibitory molecules which can stop it are thought to be 
critical for an optimal angiogenic response (Neve, Cantatore et al. 2014) (Figure 
4).  
 
 
 
Figure 4. Steps of angiogenic process. Angiogenesis is a multistep process in which, following 
pro-angiogenic stimulation, endothelial cells begin to migrate, proliferate and to form tubular 
structure. P: pericyte; BM: basement membrane; EC: endothelial cell. Modified from Blois SM. 
(Blois, Conrad et al. 2015) 
 
 
1.1.2 Angiogenesis regulating factors. 
 
There are several angiogenic factors which are involved in stimulation, 
promotion, and stabilization of new blood vessels such as: vascular endothelial 
growth factors (VEGFs), fibroblast growth factors (FGFs), angiopoietins, 
platelet-derived growth factor (PDGF), monocyte chemoattractant protein-1 
(MCP-1), transforming growth factor (TGF), various integrins, VE-cadherin, 
ephrins NO, and others (Figure 5).   
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Figure 5. Pro-angiogenic factors involved in angiogenesis. Following binding to their 
receptors on the endothelial cell membrane, pro-angiogenic factors regulate cellular processes 
(oval boxes) that are essential for angiogenesis. 
 
 
Likewise, mechanical stimulation such as physiological shear stress is also 
important particularly in arteriogenesis, that refers to maturation and 
enlargement of smaller preexisting arterial vessels through vascular remodeling 
or collateral growth (Kolluru, Bir et al. 2012).  
The VEGF family consists of few members (VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, PlGF) and distinguishes itself from other angiogenic 
superfamilies by the largely non-redundant roles of its members (Carmeliet and 
Jain 2011). VEGF-A is the best characterized and the most studied of the VEGF 
family members. It is a dimeric glycoprotein of 23-kD subunits, mitogenic for 
endothelial cells and able to induce vessel permeability (Mustonen and Alitalo 
1995). The VEGF gene, which is located on the short arm of chromosome 6 is 
composed of eight exons and it is differentially spliced to yield four mature 
isoforms (VEGF121, VEGF165, VEGF189 and VEGF206) (Tischer, Mitchell 
et al. 1991, Otrock, Mahfouz et al. 2007). 
VEGF-A is the most potent pro-angiogenic protein described to date. It exerts 
its biologic effect through interaction with cell surface receptors. These receptors 
are transmembrane tyrosine receptors and they include VEGF receptor-1 (Flt1),  
VEGF receptor-2 (KDR), selectively expressed on vascular ECs, and VEGF 
receptor-3 (FLT4). Moreover, there are also the neuropilin receptors (NP-1 and 
NP-2, also known as NRP-1 and NRP-2), that are expressed on neurons and 
vascular endothelium and act as co-receptors for the VEGFRs, increasing the 
binding affinity of VEGF to VEGRs (Ellis and Hicklin 2008). 
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In any case, the VEGF-A binding to extracellular domain of KDR receptor 
causes the dimerization and autophosphorylation of the intracellular tyrosine 
kinases domain that leads to the activation of a cascade of downstream proteins 
(Otrock, Mahfouz et al. 2007). In this way, VEGF-A induces proliferation, 
sprouting and tube formation of ECs. It affects an important number of 
angiogenic processes including wound healing, ovulation, maintenance of blood 
pressure, menstruation and pregnancy. In addition, it causes vasodilation by 
inducing the endothelial nitric oxide synthase (eNOS) and so increasing NO 
production (Otrock, Mahfouz et al. 2007). VEGF-A binds many receptors on 
hematopoietic stem cells (HSCs), monocytes, osteoblasts and neurons. It induces 
HSC mobilization from the bone marrow, monocyte chemoattraction and 
osteoblast-mediated bone formation. In mice, deletion of the VEGF-A gene is 
lethal, resulting in vascular defects and cardiovascular abnormalities (Otrock, 
Mahfouz et al. 2007).  
Other important pro-angiogenic factors are the heparin-binding protein 
mitogens, acidic and basic fibroblast growth factors (aFGF and bFGF).  
Following the binding to their high affinity tyrosine kinase FGF receptors 
(FGFRs) on the surface of target cells, FGFs lead to ECs proliferation, migration 
and production of collagenase and plasminogen activator. Indeed, FGFs 
upregulate the urokinase-type plasminogen activator (uPA) and matrix 
metalloproteinases (MMPs) production in ECs, thus promoting ECM 
degradation that represents an important step of the angiogenic process (Otrock, 
Mahfouz et al. 2007). 
Angiopoietins and their receptors have an important role in vessel maintenance, 
growth and stabilization. Angiopoietins are a family of secreted proteins that 
bind two Tie receptors, Tie1 and Tie2. Angiopoietin-1 (Ang1) is the most studied 
angiopoietin. Studies in mice demonstrated the important role of Tie receptors 
in angiogenesis. Tie1-deficient mice die either perinatally (Sato and Rifkin 
1989) or between days 13.5 and 14.5 of gestation (Puri, Rossant et al. 1995) after 
they develop edema and hemorrhage. In these mice, the vascular integrity is 
severely compromised, implying that Tie1 is necessary for the integrity and 
survival of ECs during angiogenesis (Puri, Rossant et al. 1995). Tie2-deficient 
mice die before birth and display a reduction in ECs in their blood vessels and 
the formation of abnormal vasculature including lack of branching and sprouting 
vessels (Sato and Rifkin 1989, Dumont, Yamaguchi et al. 1992), suggesting its 
crucial role for sprouting and branching of vessels (Otrock, Mahfouz et al. 2007). 
PDGF exists as heterodimer (PDGF-AB) or homodimer (PDGF-AA or -BB) 
composed of chains A and B. PDGF receptors are made up of complexes 
between α and β subtypes. In literature, it is known the role of PDGF-β receptor 
in the promotion of angiogenic sprouts in vitro. Moreover, PDGF also stimulates 
the proliferation of cultured pericytes (essential for normal microvessels 
stability) and smooth muscle cells, both of which have been shown to express 
PDGF-β receptor (Otrock, Mahfouz et al. 2007). 
Finally, the transforming growth factor-βs (TGF-β) represent a family of highly 
conserved cytokines of which TGF-β1 is one of the most common member. 
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TGF-β family ligands stimulate type II receptors that phosphorylate type I 
receptors (such as activin receptor-like kinase (ALK)) and activate the 
downstream signaling SMADs. Endoglin is a type III receptor, which facilitates 
binding of TGF-β1 to the type II receptors.  
Conversely, to the other factors described, the role of TGF-β1 is dual. Indeed, at 
low doses, TGF-β1 contributes to the angiogenic switch by upregulating 
angiogenic factors and proteinases, whereas at high doses TGF-β1 inhibits EC 
growth, promotes basement membrane reformation and stimulates smooth 
muscle cells differentiation and recruitment. Loss of TGF-β signaling 
components in mice is responsible for decreased vessel wall integrity; moreover, 
inactivation of the TGF-β1 caused lethality due to defects in the hematopoietic 
system and yolk sac vasculature (Goumans, Lebrin et al. 2003, Otrock, Mahfouz 
et al. 2007). 
 
 
1.1.3 Homeobox genes in neovascularization: specific role of 
HoxA5.  
 
Several studies have been recently involved in the definition of the role of 
homeobox genes in the regulation of neovascularization. Homeobox genes 
encode for a family of transcription factors originally discovered in Drosophila 
(Lewis 1978) and found to be highly conserved throughout the species. They 
contain the homeobox region of 183-bp coding for a 61-amino acid domain, 
containing a helix-turn-helix motif, defined as the homeodomain (HD). During 
normal development, homeobox genes act as master regulators of tissue and 
organ patterning (Krumlauf 1994, Kachgal, Mace et al. 2012). 
In mice (Hox genes) and humans (HOX genes) there are 39 genes organized into 
four Hox loci, each localized on a different chromosome (HOXA at 7p15.3, 
HOXB at 17p21.3, HOXC at 12q13.3 and HOXD at 2q31) and containing from 
9 to 11 genes (Apiou, Flagiello et al. 1996, Cantile, Schiavo et al. 2008) (Figure 
6). On the basis of sequence similarity and position on the locus, corresponding 
genes in the four clusters can be aligned with each other into 13 paralogous 
groups (Scott 1992). During mammalian development, Hox gene expression 
controls the identity of various regions along the body axis according to the rules 
of temporal and spatial co-linearity. Accordingly, the genes located mostly at 3’ 
are expressed earlier and in more anterior domains along the embryonic axes 
than the 5’ located ones (Krumlauf 1994). 
Considering the powerful role of Hox genes in normal and pathological tissue 
responses, strict regulatory mechanisms are necessary to guarantee their correct 
spatiotemporal expression pattern (Kachgal, Mace et al. 2012).  
It is widely known that homeobox genes regulate the transcription of genes 
necessary for many cell processes such as differentiation, migration and 
proliferation in both vertebrate and invertebrate (Krumlauf 1994, Gorski and 
Walsh 2000). Moreover, they play an essential role in regulating the function of 
vascular system (Douville and Wigle 2007). In particular, they coordinate the 
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processes required for proper vascular formation during development, as well as 
the maintenance and repair of the vasculature system throughout life (Murthi, 
Abumaree et al. 2014).  
 
 
 
Figure 6. Genomic organization of Drosophila homeotic genes and mammalian Hox genes. 
Each gene is represented by a colored box. Expression position on chromosome is in inverted 
order relative to body plan. Homeotic genes: lab labial, pb proboscipedia, Dfd Deformed, Scr 
Sex combs reduced, Antp Antennapedia, Ubx Ultrabithorax, abd-A abdominal-A, Abd-B 
Abdominal-B (Modified from Horabin 2013).  
 
 
Among the Hox genes with pro-angiogenic function there are genes belonging 
to the paralogue group 3. HoxA3 knockout mice died at or shortly after birth, 
with abnormalities including an absent right carotid artery and irregularly sized 
heart compartments (Chisaka and Capecchi 1991). These effects are ameliorated 
by HoxD3 insertion in the HoxA3 locus, suggesting that paralogs are 
interchangeable if expressed “properly” in space and time (Kachgal, Mace et al. 
2012). HoxD3, highly expressed in active proliferating ECs, promotes 
endothelial cell invasion of extracellular matrix early in angiogenesis and the 
subsequent capillary morphogenesis of these new vascular sprouts (Murthi, 
Abumaree et al. 2014); while, constitutes HoxB3 expression increases capillary 
morphogenesis (Cantile, Schiavo et al. 2008). 
In contrast, overexpression of HoxD10 in ECs attenuates their angiogenic 
response to FGF2 and VEGFA. Furthermore, HoxD10-expressing ECs showed 
a reduction of the angiogenic factors RHOC, MMP14, uPAR and cyclin D1 
(Kachgal, Mace et al. 2012). 
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Among the anti-angiogenic Hox genes, HoxA5 has been widely studied for its 
central role in embryo development and its involvement in diseases occurring 
during adulthood as well. 
HoxA5 gene is located on mouse chromosome 6 (and human chromosome 7) and 
encodes a 270-amino acid ANTP-class homeodomain protein (Odenwald, 
Taylor et al. 1987). 
In the mouse embryo, there is a complex organization of overlapping 
transcriptional units, which results from alternative splicing and the use of three 
different promoters: a proximal one producing 1.8kb transcript and two distal 
ones (D1 and D2) giving rise to four long RNAs (5,0(2x), 9,5 and 11,0 kb). The 
distal promoter D1 corresponds to the putative HoxA6 promoter, while the most 
distal one (D2) is located in the HoxA6–HoxA7 intergenic region downstream 
the HoxA7 gene (Jeannotte, Gotti et al. 2016) (Figure 7). 
All the HoxA5-associated transcripts include the ORF encoding HoxA5 protein, 
but only the 1.8-kb form produces the protein. However, the 5-kb HoxA6/A5 
transcript can produce the HOXA6 protein as shown by transfection assays in 
HEK293 cells. Thus, the 5-kb HoxA5, the 9.5-kb and the 11.0-kb transcripts, all 
transcribed from the D2 promoter, can be considered as long non-coding (lnc) 
RNAs (Coulombe, Lemieux et al. 2010). 
 
 
 
Figure 7. Schematic representation of the HoxA5, HoxA6 and HoxA7 gene promoter. Black, 
grey and open boxes indicate homeobox, translated and transcribed sequences, respectively. The 
two known exons of HoxA5 and the two in-frame ATG are represented. Position +1 corresponds 
to the transcription initiation site of HoxA5 exon 1. The 3′ non-coding sequences of HoxA6 exon 
2 extend further downstream into the HoxA6-HoxA5 intergenic region and the 
adjacent HoxA5 coding sequences and they are indicated by dotted lines. P, D1 and D2 represent 
the proximal, distal 1 and distal 2 promoters, respectively. HoxA5 intron is represented by a 
dotted line to indicate the non-spliced isoforms. The longest ORFs deduced from the sequence 
of each transcript are represented by waved lines: the 270 a.a. HOXA5 protein, the 381 a.a. 
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HOXA5 isoform and the HOXA6 protein. Ba, BamHI; H, HindIII; RI, EcoRI; Xh, XhoI. 
(Coulombe, Lemieux et al. 2010)  
 
 
Studies performed in mutant mice indicate that the loss of HoxA5 function is 
related to serious abnormalities in embryo development and often to death at 
birth. While heterozygous mutants (HoxA5+/-) survive with a normal lifespan and 
no obvious phenotype, HoxA5 homozygous null mutant pups (HoxA5-/-) show 
high mortality rate at birth for respiratory distress due to tracheal and lung 
dysmorphogenesis and impaired diaphragm innervation. These mutants show an 
undeveloped lung microvasculature characterized by fewer endothelial cells 
trapped within dense mesenchyme. HoxA5 is also involved in digestive tract, 
thyroid and mammary glands development and ovary homeostasis (Aubin, 
Lemieux et al. 1997, Aubin, Chailler et al. 1999, Meunier, Aubin et al. 2003, 
Garin, Lemieux et al. 2006, Gendronneau, Boucherat et al. 2012). 
Besides its central role in embryo development, HoxA5 is also expressed in 
adulthood where it is reported to have an important role in regulation of 
angiogenesis (Jeannotte, Gotti et al. 2016).  
Several studies demonstrate that HoxA5 expression is able to block angiogenesis 
in vivo and cell migration in vitro. It is expressed in quiescent, but not activated, 
endothelium (Rhoads, Arderiu et al. 2005), where stabilizes adherens junctions 
through β-catenin retention and increasing Akt1, preventing the first step of 
angiogenesis (Kachgal, Mace et al. 2012). Moreover, sustained expression of 
HoxA5 in activated cultured ECs down-regulates expression of VEGFR2, 
ephrin-A1 and IL-6 and increases the expression of the anti-angiogenic TSP-2 
(Rhoads, Arderiu et al. 2005). 
 
 
1.2 Endothelial cells dysfunction. 
 
Endothelium is a flexible organ, whose functioning well adapts to various types 
of metabolic, mechanical and inflammatory stress (Cines, Pollak et al. 1998, 
Pober and Sessa 2007). However, when this functioning becomes inadequate, 
endothelial cells dysfunction (ECD) occurs.  
ECD is a broad term which implies dysregulation of endothelial cell functions. 
It is a systemic pathological condition which can be defined as an imbalance 
between vasodilator and vasoconstrictor substances produced by the 
endothelium or overall its functions (Deanfield, Donald et al. 2005). A major 
hallmark of ECD is the impaired NO bioavailability, which is due to impaired 
NO production by the endothelium and/or increased NO inactivation by ROSs 
(Witting, Rayner et al. 2007, Kaneto, Katakami et al. 2010). Moreover, ECD is 
associated to reduced anticoagulant properties, increased platelet aggregation, 
increased expression of adhesion molecules, chemokines and cytokines, and 
increased ROSs production (Al-Isa, Thalib et al. 2010).  
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It is widely known that ECD is associated with several risk factors including 
hypercholesterolemia, smoking, hypertension, diabetes mellitus, insulin 
resistance and obesity (Brook, Bard et al. 2001). It is regarded as an important 
and early factor in the pathogenesis of atherothrombosis (Gimbrone 1999, Ross 
1999) and vascular complications of diabetes (Stehouwer, Lambert et al. 1997). 
Importantly, ECD has been shown to be of prognostic significance in predicting 
vascular events (Perticone, Ceravolo et al. 2001, Corrado, Rizzo et al. 2008), so 
endothelial function testing may potentiate the detection of cardiovascular 
diseases such as myocardial infarction, peripheral vascular disease, ischemic 
stroke, and others (Bucala, Tracey et al. 1991, Suuronen, Hazra et al. 2010, 
Kolluru, Bir et al. 2012).  
In diabetes, BM is thickened and altered in composition, due to the enhanced 
synthesis of matrix proteins by TGF-β activity (Chen, Hong et al. 2001). At the 
same time, the thickness of the glycocalyx, which contains large amounts of 
heparan sulfate proteoglycans, is markedly reduced (Nieuwdorp, Mooij et al. 
2006, Nieuwdorp, van Haeften et al. 2006). Loss of the glycocalyx leads to the 
adhesion of mononuclear cells and platelets to the endothelial surface, attenuated 
NO availability, and to an increased leakage of macromolecules through the 
endothelium of many vessels in hyperglycemia and diabetes (van den Berg, 
Nieuwdorp et al. 2006). 
The generation of ROIs and advanced glycation end-products (AGEs) also 
activates the nuclear factor kappa-B (NF-κB) pathway with, subsequently, the 
activation of numerous genes involved in inflammation, including  C reactive 
protein (CRP), platelet endothelial cell adhesion molecule-1 (PECAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion 
molecule (ICAM-1) (Pober and Sessa 2007). As they represent major receptors 
controlling the influx of monocytes and other inflammatory cells into the arterial 
wall, their expression is considered as a hallmark in the etiology of 
atherosclerosis (Gimbrone 1999).  
Finally, the regeneration function of endothelial cells, represented by 
angiogenesis, is dysfunctional in hyperglycemia and diabetes.  
 
 
1.3 Diabetes Mellitus. 
 
Diabetes mellitus (DM) is a metabolic disorder representing a leading health 
problem worldwide (Chawla, Chawla et al. 2016). According to Diabetes Atlas 
(7th edition), the global prevalence of diabetes is estimated at 415 million which 
is predicted to rise to 642 million in the next 24 years (IDF Diabetes Atlas, 7th 
edn, 2015). For this reason, DM is considered as an “epidemic” condition, 
nowadays without a cure and representing the cause of enormous human and 
economic losses (Costa and Soares 2013). 
Type 2 diabetes (T2DM) is caused by a combination of genetic factors related 
to impaired insulin secretion and insulin resistance and environmental factors 
such as obesity, overeating, lack of exercise and stress as well as ageing (Kaku, 
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2010). Chronic hyperglycemia, the main characteristic of T2DM, develops as a 
consequence of defect in insulin secretion, insulin action or both (Chawla, 
Chawla et al. 2016). It is considered as an etiological factor of endothelial barrier 
injury, as it can stimulate crosslinking and modification of matrix proteins by 
glyco-oxidation (Naka, Bucciarelli et al. 2004). 
Chronic hyperglycemia leads to micro- and macro-vascular alterations that are 
the principal causes of mortality and morbidity of diabetics. 
Indeed, diabetic patients often show poor wound healing, impaired collateral 
formation after vascular occlusion or myocardial infarction, and also an 
increased risk of rejection of transplanted organs (Martin, Komada et al. 2003).  
For this reason, DM is considered not only a metabolic but also a vascular 
disease characterized by the so called “angiogenic paradox” in which both anti- 
and pro-angiogenic conditions co-exist in different tissues. This paradox 
indicates that local microenvironment of each organ definitely plays a very 
important role in the angiogenic process (Costa and Soares 2013). 
 
 
1.3.1 Vascular complications associated to diabetes: micro- vs 
macro-vascular disease. 
 
Microvessels are the basic functional unit of the cardiovascular system 
comprising of arterioles, capillaries, and venules (Orasanu and Plutzky 2009). 
They differ from macrovessels in both their architecture and cellular 
components. In contrast to macrovessels that supply blood to organs, 
microvessels play important roles in maintaining blood pressure and proper 
nutrient delivery (Orasanu and Plutzky 2009). The microcirculation also has 
regulatory systems controlling vascular permeability and myogenic responses 
that can adapt blood flow according to local metabolic needs.  
Microvascular disease affects microvessels and it is manifested as retinopathy, 
nephropathy and neuropathy, clinically resulting in blindness, kidney failure and 
nerve damage. Macrovascular disease, instead, affects medium and large caliper 
vessels, often leading to atherosclerosis and thromboembolism. Clinically, this 
translates into coronary, carotid, cerebrovascular disease as well as diseases of 
peripheral vessels, which are more prevalent in the arteries of the distal segment 
of the lower limbs (Costa and Soares 2013) (Figure 8).  
Patients with DM appear particularly at higher risk of accelerated atherosclerosis 
which ultimately culminates in cerebrovascular and cardiovascular events and 
premature death (Kalofoutis, Piperi et al. 2007). 
Several studies show that intensive treatment of hyperglycemia is able to reduce 
the progression of microvascular disease, but not macrovascular (Ahmad, He et 
al. 2005). This is explained by the different response of large and small vessel 
endothelium to insulin and glucose (Wang, Chen et al. 2009). It is reported that 
hyperglycemia is not a determining factor for macrovascular disease since an 
increase in glycosylated hemoglobin (HbA1c) from 5.5 to 9.5 % implies a two-
fold increase in the incidence of macrovascular disease, but the same increase in 
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HbA1c implies a ten-fold increase in microvascular disease (Wang, Chen et al. 
2009, Costa and Soares 2013). 
 
 
 
Figure 8. Diabetic vascular diseases.  Diabetes affects vasculature in different body tissues 
leading to micro and macrovascular complications. Main symptoms are indicated for each 
condition. (Kolluru, Bir et al. 2012) 
 
 
- Macrovascular complications 
Atherosclerotic-associated coronary artery disease is a major cause of mortality 
in diabetics. The first step in the development of atherosclerotic plaque, is the 
endothelial damage followed by the formation of a fatty streak, a yellow lesion-
fatty plaque, which develops well demarcated edges, and evolves to fibrous 
plaques, which are whitish lesions with a lipid-rich core (Rosenfeld 2000). The 
enlargement of the necrotic core followed by the rupture of these plaques causes 
luminal thrombosis in acute coronary syndrome, which occurs in 75% of patients 
who die of an acute myocardial infarction (Davies and Thomas 1984). 
Among the causes leading to destabilization and plaque rupture an important role 
is played by intra-plaque hemorrhage (Kolodgie, Gold et al. 2003, Costa and 
Soares 2013). Indeed, red blood cell (RBC) membranes are rich in phospholipids 
and free cholesterol. Moreover, most intraplaque vasa vasorum are 
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endothelialized, but only few of them have mural cells such as pericytes and 
VSMCs. This lack of mural cells may contribute to vessel leakiness because such 
vessels are fragile and therefore easily damaged. This damage results in the 
development of immature vessels within the lesion, which are associated with 
abnormal angiogenesis (Costa and Soares 2013). 
 
 
- Microvascular complications 
Several are the microvascular alteration that may occur in diabetes, and these 
involve several tissues such as retina, nerve, skin and kidney.  
 
- Diabetic Retinopathy 
Diabetic retinopathy (DR) is one of the comorbidities of type 1 and 2 diabetes.  
It consists of two phases: the first, characterized by an alteration of retina 
microvasculature and capillary degeneration (Durham and Herman 2011), with 
capillary pericyte loss and chronic hypoxia; the second in which there is a 
“super-compensatory” response (Durham and Herman 2011), announced by 
neovascularization and proliferative changes. Ultimately, DR results in the loss 
of visual acuity secondary to macular edema, formation of neo-vessels and 
bleeding or neo-vascular glaucoma (Costa and Soares 2013). 
The etiopathogenesis of retinopathy is multifactorial (Costa and Soares 2013) 
and the risk of development, in patients with T2DM, is related to both severities 
of hyperglycemia and presence of hypertension (Chawla, Chawla et al. 2016).  
Besides the brain, the retina is one of the tissues in human body using the higher 
amount of oxygen. Hyperglycemia may cause a hypoxic state, thus triggering 
compensatory mechanisms; however, this only partially explains the 
development of retinopathy in diabetic patients, indeed not all diabetics show 
proliferative lesions in their retinas. Moreover, there is increasing evidence that 
oxidative stress can cause retina damage, leading to diabetic retinopathy and 
macular edema (Costa and Soares 2013).  
 
- Diabetic nephropathy  
Diabetic nephropathy is the leading cause of end-stage renal disease worldwide. 
Moreover, many associated cardiovascular events can develop following renal 
degeneration (Xu, Kanasaki et al. 2012). Indeed, in many studies it has been 
well-established a direct association between the presence of microalbuminuria 
and macrovascular complications (Hagg, Thorn et al. 2013). 
Similarly to what happen in DR, diabetic nephropathy is characterized by 
abnormal angiogenesis due to VEGF overexpression (Xu, Kanasaki et al. 2012).  
The pathogenic mechanisms underlying diabetic nephropathy involve 
generation of ROSs, accumulation of AGEs and activation of intracellular 
signaling molecules, such as protein kinase C (PKC) (Chawla, Chawla et al. 
2016). Among the causes leading to the onset and progression of nephropathy, 
the involvement of pro-inflammatory cytokine, such as IL-1, IL-6, IL-18, TNF-
α and TGF-β1, play a pivotal role. Inflammatory activity increases vascular 
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permeability, thickening of glomerular BM, ECs apoptosis and chronic 
inflammation. Moreover, oxidative stress, hyperglycemia and diacylglycerol 
increase TGF-β1 production, facilitating ECM formation through mesangial 
cells, contributing to hypertrophy of renal cells and increasing collagen synthesis 
(Costa and Soares 2013). 
 
- Neuropathy and impaired skin wound healing   
Diabetic neuropathy is one of the complications induced by microvascular 
changes and affecting almost half of diabetic patients. Diabetic neuropathy is 
associated with foot ulcers, gangrene and limb amputation (Costa and Soares 
2013, Chawla, Chawla et al. 2016).  
The risk of diabetic neuropathy development is directly proportional to both 
duration and magnitude of hyperglycemia. Although the precise nature of the 
injury to the peripheral nerves due to hyperglicemia is not certain yet, activation 
of the polyol pathway, AGEs accumulation and enhanced oxidative stress 
induced by hyperglycemia have been implicated in the pathogenesis of 
neuropathy. The peripheral nerves damage could be due to injury on nerve tissue 
or on endothelial cells or vascular dysfunction (Chawla, Chawla et al. 2016). 
In diabetics, chronic ulcers are also associated to an impairment of wound 
healing capacity. In this process, microangiopathy may also contribute to defects 
in the nutrient/oxygen supply, thus inhibiting normal healing process (Xu, 
Kanasaki et al. 2012). 
 
 
1.4 Molecular mechanisms underlying endothelial damage: role 
of chronic hyperglycemia. 
 
A wide number of studies performed both in animals and in humans proved that 
chronic hyperglycemia, as well as acute hyperglycemia, impairs endothelial 
function in both macro- and micro-vasculature (Ceriello 2010, Grassi, Desideri 
et al. 2012, Sena, Pereira et al. 2013).  
Hyperglycemia causes vascular damage in different cell types of the vascular 
wall. There are several mechanisms involved in this damaging effect including: 
1) increased flux of glucose and other sugars through the polyol pathway; 2) 
increased intracellular formation of AGEs; 3) increased expression of the 
receptor for AGEs (RAGE) and its activating ligands; 4) activation of PKC 
isoforms and 5) overactivation of the hexosamine pathway (Figure 9).  
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Figure 9. Molecular pathways activated by hyperglycemia. Excess of superoxide partially 
inhibits the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), thereby 
directing upstream metabolites from glycolysis into pathways of glucose overutilization. The 
result is an increase of dihydroxyacetone phosphate (DHAP) to diacylglycerol (DAG), that 
activates PKC, and of triose phosphates, that are converted to methylglyoxal, the main 
intracellular AGE precursor. Increased flux of fructose-6-phosphate to UDP-N-
acetylglucosamine increases modification of proteins by O-linked N-acetylglucosamine 
(GlcNAc) and increased glucose flux through the polyol pathway consumes NADPH and 
depletes GSH (Brownlee 2001). 
 
 
Oxidative stress has been identified as the common leading cause of these 
pathways (Brownlee 2001). Indeed, ROSs decrease the metabolism of glucose 
through glycolysis increasing the flux through the alternative polyol and 
hexosamine pathways. Moreover, oxidative stress leads to DNA damage and 
activation of nuclear poly(ADP-ribose) polymerase (PARP) that in turn 
increases production of polymers of ADP-ribose reducing glyceraldehyde 3-
phosphate dehydrogenase activity. Ultimately the levels of all upstream 
glycolytic intermediates increase. The accumulation of glycolytic intermediates 
activates damaging mechanisms: PKC pathway, hexosamine and polyol 
pathways and AGEs formation. The overall effects of these mechanisms are 
increased oxidative stress, apoptosis and vascular permeability (Sena, Pereira et 
al. 2013). Additionally, glucotoxicity induces a low-grade proinflammatory 
condition, due to the activation of transcription factors such as NF-κB (Creager, 
Luscher et al. 2003, Brownlee 2005, D'Souza, Hussain et al. 2009).  
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- Nuclear Factor-κB (NF-κB) activation. 
One of the intracellular targets of hyperglycemia and oxidative stress is the 
transcription factor NF-κB (Evans, Goldfine et al. 2002).  
NF-κB is a key mediator regulating multiple proinflammatory and pro-
atherosclerotic target genes in ECs, VSMCs and macrophages (Sena, Pereira et 
al. 2013). As demonstrated by Bierhaurs et al., a sustained activation of NF-κB 
is reached by activation of AGEs/RAGE pathway (Bierhaus, Schiekofer et al. 
2001). 
In absence of stimuli, NF-κB is confined in the cytoplasm as an inactive 
heterodimer, consisting of the p50 and p65 subunits complexed with an inhibitor 
protein subunit, IκB. Following stimulation, a signaling cascade activates NF-
κB-inducing kinase (NIK) and NF-κB-activating kinase (NAK) that activate IκB 
kinase (IKK) by phosphorylation on serine residues. 
IKK is a heterotrimeric complex consisting of two catalytic subunits IKK-α (also 
called IKK1) and IKK-β (also called IKK2) and a regulatory subunit, IKK-γ. 
Although both IKK-α and IKK-β subunits are subjected to serine 
phosphorylation, only substitution of these sites in IKK-β completely prevents 
the activation of total IKK activity (Delhase, Hayakawa et al. 1999, Evans, 
Goldfine et al. 2002). 
Once activated, IKK phosphorylates IκB leading to its ubiquitination and 
subsequent degradation. In this way, NF-κB is free to translocate to the nucleus 
where it mediates the expression of a large number of genes, including growth 
factors (e.g., VEGF), proinflammatory cytokines (e.g., TNF-α and IL-1β), 
RAGE, adhesion molecules (e.g., VCAM-1) and others. 
Enzymes that catalyze the ubiquitination and degradation of phospho-IκB are 
constitutively active, indicating that the principal regulatory step in the 
activation of NF-κB is IκB phosphorylation (Evans, Goldfine et al. 2002) (Figure 
10).   
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Figure 10. NF-κB activation. Several stimuli (i.e. glucose, FFA, oxidative stress) contribute to 
NF-κB activation. NF-κB is confined in the cytoplasm in an inactive form complexed with its 
inhibitor subunit protein IκB. Following IκB phosphorylation, NF-κB translocate to the nucleus 
where activates the transcription of pro-inflammatory genes. (Evans, Goldfine et al. 2002) 
 
 
- Advanced Glycation End products (AGEs) pathways activation. 
AGEs constitute a heterogeneous group of compounds formed by a combination 
of glycation, oxidation and/or carbonylation, which can be divided into three 
distinct pathways (de Vos, Lefrandt et al. 2016) (Figure 11). 
The Maillard reaction, the classical mechanism of AGEs formation, is a non-
enzymatic process in which glucose or other reducing sugar such as galactose 
and fructose spontaneously react with aminoacids, nucleotide bases or fatty acids 
forming glycated molecules.  
In particular, in these slow non-enzymatic reactions, carbonyl groups of reducing 
sugars react with amino group of proteins to form Schiff bases within a few 
hours. This is followed by intramolecular rearrangement of Schiff bases that 
results in more stable, but still reversible, Amadori products. 
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Figure 11. Formation of advanced glycation end products (AGEs). AGEs are formed through 
three different pathways. The Maillard reaction takes place extracellularly; lipid peroxidation 
takes place both extra and intracellularly and glycolysis pathway occurs intracellularly (de Vos, 
Lefrandt et al. 2016). 
 
 
An example of an Amadori product is glycated hemoglobin, widely used in 
clinical practice as glycation index and for diagnosis of diabetes mellitus.  
Then, the slow process of oxidation of the Amadori products lead to reactive 
carbonyl compounds and subsequently to the formation of AGEs within weeks 
to months. The best-known AGEs derived from this glycoxidation process are 
pentosidine, Nε-carboxymethyl-lysine (CML) and glucosepane (de Vos, 
Lefrandt et al. 2016). 
Other and much faster evolving processes leading to AGEs formation are lipid 
peroxidation and glycolysis.  
The lipid peroxidation pathway take place both intracellularly and 
extracellularly. In this process, ROSs alter lipids into reactive carbonyl 
compounds under influence of oxidation. This formation results into AGEs or 
advanced lipid end products (ALEs), for example malondialdehyde. 
Finally, during the intracellular glycolysis pathway, glucose is altered into 
reactive carbonyl compounds, of which the best-known is Methylglyoxal 
(MGO). The chemical reaction between reactive carbonyl compounds and 
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proteins can result in AGEs. An example of AGEs formed by this pathway is 
MGO-derived hydroimidazolone (MGO-H1) (Jaisson and Gillery 2010). 
Besides endogenous formation of AGEs, a certain amount of them can be 
absorbed through two mechanisms. The first is the inhalation of tobacco smoke, 
considering that it contains highly reactive glycation products which rapidly 
form AGEs in vitro and in vivo. Indeed, it has been shown that serum AGEs are 
significantly elevated in smokers who smoke at least a package a day as 
compared to nonsmokers (Koschinsky, He et al. 1997). 
The second is the intake of high-AGE food products. Indeed, the temperature at 
which food products are prepared is of major importance for the amount of AGEs 
formed in processed food, with oven frying as the most severe inducer 
(Goldberg, Cai et al. 2004). Approximately 10% of the AGEs from food products 
and beverages are absorbed from the gastrointestinal tract into the blood 
(Koschinsky, He et al. 1997). For example, serum CML increased after a 6-week 
high-AGE diet and decreased in low-AGE diet in patients with diabetes mellitus 
(Cai, He et al. 2004, de Vos, Lefrandt et al. 2016). 
Several studies demonstrate that AGEs have an important role on vasculature 
contributing to the development of micro- and macro-vascular complication. 
Many are the mechanisms by which accumulation of AGEs lead to the alteration 
of structure and function of different cell types. 
First of all, AGEs form cross-link with molecules of ECM. As an example, 
collagen and elastin cross-link causes tissue stiffness. 
Following the binding with their cell membrane receptor, RAGE, AGEs activate 
intracellular pathways inducing the activation of NF-κB and its target genes, thus 
promoting the consequent release of pro-inflammatory molecules (de Vos, 
Lefrandt et al. 2016). Moreover, AGE-bound RAGE increases endothelial 
permeability to macromolecules. 
AGEs are also responsible for the impairment of the balanced release of NO and 
ET-1. In particular, AGEs decrease NO bioavailability and eNOS expression 
while increase expression of ET-1 in ECs  to favor vasoconstriction and 
endothelial dysfunction (Sena, Pereira et al. 2013).  
Besides the vasculature, accumulation of AGEs due to hyperglycemic condition 
impair insulin sensitivity of skeletal muscle. Previously in our lab, it has been 
demonstrated that, in both L6 myotubes and in mice fed a high AGEs diet, 
human glycated albumin (HGA) induces insulin resistance by activating protein 
kinase C α(PKCα), through the formation of a multimolecular complex 
including RAGE/IRS-1/Src and PKCα (Miele, Riboulet et al. 2003, Cassese, 
Esposito et al. 2008).    
Finally, AGEs are also associated to physiological aging and neurodegenerative 
diseases (Bierhaus and Nawroth 2009, Schlotterer, Kukudov et al. 2009).  
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1.5 Methylglyoxal metabolism. 
 
The most important AGE precursor is MGO, a α-oxoaldehyde defined as 
dicarbonyl for the presence in its structure of 2 adjacent carbonyl groups that 
make this compound highly reactive. Endogenous MGO is derived from 
metabolic intermediates of carbohydrates, proteins and fatty acids (Fleming, 
Humpert et al. 2011).  
In mammals, the major amount of MGO is formed at relatively high flux as a 
byproduct of glycolysis by non-enzymatic degradation of triosephosphates, 
glyceraldeide-3 phosphate (G3P) and dihydroxyacetone phosphate (DHAP) 
(Phillips and Thornalley 1993), with a formation rate of about 120 μM/day in 
normoglycemic conditions (Thornalley 1988). This rate is increased in 
conditions leading to higher triosephosphate concentration, like happens in 
hyperglycemia where glucose metabolism is increased, impairment of pentose 
pathway with decreased G3P or increased anaerobic glycolysis occurring in 
hypoxia (Nigro, Leone et al. 2017). 
Even if MGO formation through the glycolysis constitute only 0.1% of the 
glucotriose flux, its biological effect is important considering the high reactivity 
with proteins and nucleic acids (Maessen, Stehouwer et al. 2015). 
Besides glycolysis, minor sources of MGO are: the oxidation of acetone and 
aminoacetone, the catabolism of ketone bodies, that are increased in diabetic 
ketoacidosis, the catabolism of threonine, autoxidation of glucose, degradation 
of proteins glycated and lipid peroxidation (Rabbani, Xue et al. 2016). 
Despite endogenous MGO formation, a certain amount of exogenous MGO 
derives from dietary. In particular, extremely high levels of MGO were found in 
natural products, such as honey and processed food and beverages such as 
sweetened soft drink, fruit juice, bread/cakes and others foodstuff. Moreover, 
also the heating process, prolonged storage and fermentation or polluted air, like 
tobacco smoke, contribute to MGO formation (Rabbani, Xue et al. 2016, Nigro, 
Leone et al. 2017). 
Anyway, the contribution of exogenous MGO on human health is still 
controversial. Indeed, some studies report that during digestive process, free 
MGO is rapidly degraded in the intestine (Degen, Vogel et al. 2013) while others 
report that in rodents fed with MGO-supplemented diet there are a brain and 
plasma MGO accumulation (Cai, Uribarri et al. 2014). 
Although MGO concentration have frequently been measured in tissues and 
plasma of various species, the values are highly variable in dependence of the 
different analytical methods used (Maessen, Stehouwer et al. 2015). Anyway, in 
physiological conditions, MGO levels have been estimated to be about 50-150 
nM in the plasma and 1-4 µM in tissues (Rabbani and Thornalley 2014). When 
dicarbonyl concentrations increase beyond these, protein and cell dysfunction 
occur leading to impaired health and pathological conditions. 
Effectively, MGO concentrations are increased by 5-6-fold in patients affected 
by T1DM and by 2-3-fold in T2DM patients (McLellan, Thornalley et al. 1994).  
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The accumulation of MGO can be prevented by several pathways of 
detoxification. Among these, the most important enzymatic detoxification is 
accomplished by the glyoxalase system, which major role is to suppress 
dicarbonyl stress in physiological systems, keeping dicarbonyl metabolites at 
low, tolerable levels. Under physiological conditions, >99% of MGO is 
detoxified by the glyoxalase system. Minor pathways of MGO detoxification 
include aldehyde dehydrogenase (ALDH) and aldose reductase (AR) converting 
MGO to pyruvate and hydroxyacetone, respectively (Maessen, Stehouwer et al. 
2015) (Figure 12). 
 
 
 
Figure 12. Pathways leading to MGO formation and detoxification. MGO is mainly formed 
as a byproduct of glycolysis. Other sources of MGO are constitute by: autoxidation of glucose, 
catabolism of threonine and acetone, lipid peroxidation and degradation of glycated proteins. 
The glyoxalase system is the most important pathway of MGO detoxification. Other minor 
pathways are aldehyde dehydrogenase (ALDH) and aldose reductase (AR). When MGO 
accumulates, it reacts with arginine to form MG-H1, H2, H3, argpyrimidine (AP), 
tetrahydropyrimidine (THP). When MGO reacts with lysine forms Nε-(1-carboxyethyl)lysine 
(CEL) and 1,3-di(Nε-lysino)-4-methyl-imidazolium (MOLD), while it forms 2-ammonio-6-{(2-
[(4-ammonio-5-oxido-5-oxopentyl)amino]-4-methyl-4,5-dihydro-1H-imidazol-5-ylidene) 
amino}hexanoate (MODIC) following dimer crosslink with arginine and lysine. (Maessen, 
Stehouwer et al. 2015) 
 
 
The glyoxalase system is present in the cytosol of all cells and consists of two 
enzymes, glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2), and a catalytic amount 
of glutathione (GSH). The rate limiting enzyme Glo1 converts the spontaneously 
formed MGO-GSH hemithioacetale to the thioester S-D-lactoylglutathione. Its 
activity is directly proportional to GSH concentration, thus in oxidative stress, 
where cellular GSH concentration is reduced, there is an associated impairment 
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of Glo1 activity. Glo2 catalyzes the hydrolysis of S-D-lactoylglutathione to D-
lactate and GSH (Thornalley 1993, Nigro, Leone et al. 2017) (Figure 13). 
 
 
 
Figure 13. The Glyoxalase System. Glyoxalase system is formed by two enzymes. Glyoxalase 
1 catalyzes the conversion of the spontaneously formed MGO-GSH hemithioacetal to the 
thioester S-D-lactoylglutathione. Glyoxalase 2 catalyzes the hydrolysis of S-D-
lactoylglutathione to form the end-product D-lactate. (Maessen, Stehouwer et al. 2015) 
 
 
The GLO1 gene is ubiquitously expressed in all tissues of prokaryotic and 
eukaryotic organisms (Thornalley 2003). Mouse Glo1 is located on chromosome 
17, while human GLO1 locus is on chromosome 6 and encodes for a 
homodimeric Zn2+ -dependent isomerase of which the two monomers are formed 
by means of non-covalent bonds. The dimer has molecular mass of 46 kDa and 
exists as three alloenzymes: Glo1-1, Glo1-2 and Glo2-2 (Thornalley 2003).  
The activity of Glo1 is variable during the life. In fetal tissue, Glo1 activity is 
about 3 times higher than in corresponding adult tissues (Thornalley 2003). 
Moreover, studies performed at first in C. Elegans (Morcos, Du et al. 2008) and 
then confirmed in rodents (Fleming, Theilen et al. 2013), indicate that there is a 
physiological decrease of Glo1 activity and expression with age. 
In literature, there are several studies demonstrating that Glo1 activity can be 
modulated by both gene expression regulation and post-translational 
modifications. For example, Glo1 activity is reduced following the interaction 
with the GSH-NO adduct S-Nitrosoglutathione that converts Glo1 into an 
inactive form (Mitsumoto, Kim et al. 2000). Moreover, Glo1 activity is also 
modified by phosphorylation on Thr107 and nitrosylation on Cys139 (Maessen, 
Stehouwer et al. 2015). 
In hypoxic conditions, hypoxia inducible factor 1-α (HIF1-α) negatively 
regulates Glo1 expression binding an antioxidant- response element (ARE) 
located on its promoter. In this way, hypoxia is an important driver of dicarbonyl 
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stress increasing anaerobic glycolysis and thus MGO formation and decreasing 
Glo1 expression (Seagroves, Ryan et al. 2001, Nigro, Leone et al. 2017). 
In contrast, basal and inducible Glo1 expression is controlled by nuclear factor 
erythroid 2-related factor (Nrf2) through the binding to AREs (Xue, Rabbani et 
al. 2012). The regulation mediated by Nrf2, is antagonized by NF-κB-p65. 
Indeed, in pro-inflammatory state, typical condition of diabetes and obesity, 
there is a constitutive activation of NF-κB that, through the inhibition of Nrf2, 
impairs Glo1 expression (Liu, Qu et al. 2008). Moreover, the latter is also 
negatively regulated by the activation of RAGE and, again, NF-κB (Rabbani, 
Xue et al. 2014). 
It is also reported that GLO1 gene is a hotspot for functional copy number 
variation (CNV) that leads to an increase of 2-4-fold of Glo1 expression (Redon, 
Ishikawa et al. 2006, Cahan, Li et al. 2009). Anyway, further investigations are 
crucial to understand if these variations are useful against MGO accumulation 
and damage. 
 
 
1.5.1 Damaging effect of Methylglyoxal on vascular function. 
 
MGO accumulation is linked to age-related disease such as diabetes, obesity, 
central nervous disorders and cardiovascular disease, in which endothelial 
dysfunction is a common feature (Nigro, Leone et al. 2017). Emerging evidence 
have been highlighted the harmful effect of MGO accumulation on vasculature; 
it is known that MGO is crucial in the development of diabetic complications 
playing a damaging effect both on macro- and micro-vasculature. 
MGO interacts mainly with arginine residues to form MGO-H1 that is the most 
prevalent MGO-derived AGE found in vivo, leading to structural change, 
inactivation and degradation of target proteins (Schalkwijk 2015, Nigro, Leone 
et al. 2017). The interaction of MGO with arginine on serum albumin is 
responsible for the inhibition of antioxidant capacity and induces an increased 
synthesis and secretions of proinflammatory markers (TNF-α, IL-1β) in 
monocyte. Other important MGO-H1 protein are haemoglobin, lens proteins and 
collagen. In particular, modification of type IV collagen leads to decreased 
integrin binding, detachment of endothelial cells from vascular wall and 
inhibition of angiogenesis. Moreover, MGO causes the impairment of 
physiological angiogenesis through a RAGE-mediated autophagy-induced 
VEGFR2 degradation (Liu, Yu et al. 2012). 
An increase of MGO-H1 modifications of mitochondrial proteins are linked to 
increased oxidative stress (Maessen, Stehouwer et al. 2015).  In turn, oxidative 
stress induced by MGO is linked to the impairment of endothelium-dependent 
vasodilation. Indeed, a study performed in rat aortic tissue indicates that 
acetylcholine-induced vasodilation is impaired by MGO and this effect is 
attenuated by treatment with MGO scavengers (aminoguanidine and N-acetyl-
cisteine) (Dhar, Dhar et al. 2010) and by Glo1 overexpression (Brouwers, 
Niessen et al. 2010).  
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Another target of MGO is represented by eNOS; indeed, it has been 
demonstrated that long-term MGO treatment of rat isolated mesenteric artery 
induces a reduction of protein levels and phosphorylation on the active site 
(Ser1177) of this protein (Mukohda, Morita et al. 2013). 
In contrast, antioxidants like polyphenols prevent MGO-dependent impairment 
of NO release, improving vasodilation in mouse corpora cavernosa (Goueslard, 
Cottenet et al. 2016). Moreover, age-related glycative and oxidative stress is 
reduced in Glo1 transgenic rats (Jo-Watanabe, Ohse et al. 2014). 
The involvement of MGO in the pathogenesis of atherosclerosis and 
development of macrovascular diabetic complications is demonstrated by 
several studies performed in animal models and humans. Vulesevic B et al. 
demonstrate how MGO, in diabetic mice, is involved in development of 
cardiomyopathy increasing inflammation and endothelial cell loss (Vulesevic, 
McNeill et al. 2016). In line with this, MGO treatment of Goto-Kakizaki rats 
exacerbate endothelial dysfunction in part increasing oxidative stress, AGEs 
formation and inflammation (Sena, Matafome et al. 2012). Moreover, MGO high 
levels induce vascular contractile dysfunction in arterial walls of spontaneously 
hypertensive rats (Mukohda, Okada et al. 2012) and activates NF-κB through 
RAGE, thus increasing rennin-angiotensin levels and blood pressure in Sprague-
Dawley rats  (Dhar, Dhar et al. 2014, Nigro, Leone et al. 2017) (Figure 14). 
 
 
 
 
Figure 14. Main mechanisms of MGO action. AGEs, advanced glycation end products; ECM, 
extracellular matrix; ERK, extracellular signal-regulated kinase; GLO1, glyoxalase 1; GLO2, 
glyoxalase 2; GSH, reduced glutathione; JNK, c-jun N-terminal kinase; MG, methylglyoxal; 
NADPHox, nicotinamide adenine dinucleotide phosphate oxidase; NF-κB, nuclear factor -κB; 
ROSs, reactive oxygen species.(Matafome, Rodrigues et al. 2016) 
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Besides macro-vasculature, MGO has a harmful effect on microvasculature, 
contributing to the pathogenesis of diabetic nephropathy, retinopathy and 
neuropathy. In particular, exposure of cultured cells and kidneys from diabetic 
mice to high levels of MGO sensitize microvascular ECs to inflammatory effects 
of TNF-α (Yao, Taguchi et al. 2007). Moreover, overexpression of Glo1 in 
streptozotocin-induced diabetic rats improves renal function and protects against 
albuminuria (Liu, Zhu et al. 2013, Geoffrion, Du et al. 2014). MGO induces 
blood brain barrier damage by increasing permeability of brain endothelial cells 
(Toth, Walter et al. 2014).  
Increased serum levels of MGO-H1 are associated to the development of diabetic 
retinopathy (Fosmark, Torjesen et al. 2006), while Glo1 overexpression protects 
against premature death of pericytes and ECs (Miller, Smith et al. 2006). 
Moreover, MGO also induces cell death via NF-κB activation in diabetic lens 
(Kim, Kim et al. 2012, Maessen, Stehouwer et al. 2015). Finally, Fleming et al. 
(Fleming, Theilen et al. 2013) demonstrated in a study performed in mice that 
aging-dependent reduction of Glo1 delays wound healing. 
In light of this evidence, appears clear that the regulation of MGO concentrations 
is crucial for preserving vascular function.  
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2. AIM OF THE STUDY 
 
DM is a metabolic disease representing a leading health problem worldwide. 
Diabetic patients are exposed to a higher risk to develop micro-and macro-
vascular complications responsible for the high mortality of associated to DM. 
Chronic hyperglycemia is the main characteristic of diabetes and constitutes a 
primary factor in the development of diabetic vascular complications. A common 
feature of these complications is the alteration of angiogenesis. 
In the last decades, extensive research has been focused on the identification of 
the causes that lead to the onset and progression of diabetic complications. 
However, given the complexity of these phenomena, the underling molecular 
mechanisms are not fully understood yet. 
Previously, we and others have demonstrated that MGO, a product of chronic 
hyperglycemia, is responsible for endothelial dysfunction.  
The aim of this study is to evaluate the effect of MGO on the angiogenic process 
of endothelial cells in order to identify the molecular mechanisms by which this 
reactive dycarbonyl may impair the vascular function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
33 
 
3. MATERIALS AND METHODS 
 
Reagents. Media, sera and antibiotics for cell culture were from Lonza 
(Walkersville, MD, USA). Protein electrophoresis and western blot reagents 
were from Bio-Rad (Richmond, VA, USA) and ECL reagents from Pierce 
(Rockford, USA). The used antibodies were anti-HoxA5 (Abcam, Cambridge, 
UK), anti- NF-κB -p65, anti-GAPDH, anti-Cyclin-G1 from Santa Cruz 
Biotecnology (CA, USA), anti-α-Tubulin (Sigma-Aldrich, St Luis, MO, USA). 
TRIzol and SuperScript III were from Invitrogen (Carlsbad, California, USA). 
SYBR Green Supermix was from Bio-Rad (Hercules, California, USA). DNA 
Purification Kit and pGEM-T EASY Vector were from Promega (Madison, 
Wisconsin, USA). NF-κB Activation Inhibitor (JSH-23) was from Santa Cruz 
Biotecnology (CA, USA). The QIAquick PCR Purification kit was from 
QIAGEN (Hilden, Germany). All other chemicals were from Sigma (St Louis, 
MO, USA).  
 
Cell culture procedure. Mouse aortic endothelial cells (MAECs) isolated 
by C57/bl6 (WT) and Glyoxalase 1 heterozygous knockdown (Glo1KD) mice 
were kindly provided by Dr. T.H. Fleming (Department of Medicine I and 
Clinical Chemistry, University Hospital Heidelberg). MAECs were plated in T75 
flask and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 
1 g/l glucose supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-
glutamine and 0.1 mM non-essential amino acids. Cell cultures were maintained 
at 37 °C in a humidified atmosphere containing 5% (v/v) CO2.  
 
Cytoplasmic and nuclear fractionation. Nuclear and cytoplasmic 
proteins were isolated using the NE-PER Nuclear and Cytoplasmic Extraction 
Kit purchased from Thermo Fisher Scientific (Waltham, Massachusetts, USA), 
according to the manufacturer’s instructions. Where indicated, cells were treated 
overnight with 60μM JSH-23. 
 
Western blot analysis. Cells were solubilized in lysis buffer (50 mM 
HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10 mM Na2P2O7, 2 mM 
Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride and 10 μg/ml aprotinin) for 2 h at 4°C. Cell lysates 
were clarified by centrifugation at 16,000 g for 20 min. Cell lysates were then 
separated by SDS-PAGE and transferred into 0.45-μm Protran Nitrocellulose 
Membrane (Sigma-Aldrich, St Luis, MO, USA). Upon incubation with primary 
and secondary antibodies, immmunoreactive bands were detected by 
chemiluminescence and densitometric analysis was performed using ImageJ 
software. 
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RNA isolation, reverse transcription and Real Time-PCR. Total 
RNA was isolated from MAECs using TRIzol reagent, according to the 
manufacturer’s protocol. After quantification with NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA), 1 μg of total RNA 
was reverse transcribed using SuperScript III according to the manufacturer’s 
instructions. The cDNA obtained was used as a template for Real Time-PCR, 
performed in triplicate by using iQ SYBR Green Supermix on iCycler Real Time 
detection system (Bio-Rad). Relative quantification of gene expression was 
calculated by the ΔΔ-Ct method. Each Ct value was first normalized to the 
respective Cyclophilin A Ct value of a sample to account for variability in the 
concentration of RNA and in the conversion efficiency of the reverse 
transcription reaction. Specific primers used for amplification were purchased 
from QIAGEN (Hilden, Germany) and listed in the table below (Table 1): 
 
Cyclophilin A Forward 5'-GCAGACAAAGTTCCAAAGACAG- 3' 
Reverse   5'-CACCCTGGCACATGAATCC- 3' 
Glo1    Forward 5’-CCCTCGTGGATTTGGTCACA-3’ 
Reverse 5’-AGCCGTCAGGGTCTTGAATG-3’ 
HoxA5 Forward 5’-CCCAGATCTACCCCTGGATG-3’ 
Reverse 5’-CAGGGTCTGGTAGCGAGTGT-3’ 
NF-κB-p65                      Forward 5’-CTGATGTGCATCGGCAAGTG -3’ 
Reverse 5’-CTCTTCAATCCGGTGGCGAT-3’ 
 
Table 1: Primer sequences used for Real Time-PCR analysis. 
 
Cell transfection. 1x105 MAECs were seeded in 60-mm plates. After 18 
hours, HoxA5 expression was modulated by transfecting MAECs with HoxA5-
siRNA 5 nM (Origene, Rockville, MD, USA) and negative control (scramble). 
TransIT-X2 purchased from Mirus Bio LCC (Madison, WI, USA) was used as 
transfection reagent, according to the manufacturer’s instructions. Cells were 
incubated with complete medium for 48 hours before starvation. 
 
Quantification of MGO. Intracellular MGO concentration was measured 
in WT and Glo1KD MAECs extracts by HPLC after derivatization with 1,2-
diamino-4,5-dimethoxybenzene as previously described (McLellan, Phillips et 
al. 1992). 
 
Cell growth assay. 5x104 cells were seeded in MW-6 and cell growth was 
monitored at 0, 12, 24, 48, 72, 96 hours by automated cell count with TC10TM 
Automated Cell Counter (Bio-Rad). 
 
Transwell migration and invasion assay. Cells were serum starved for 
5 hours. After trypsinization, 1x105 cells/well were plated on the upper side of 
12-well cell culture inserts (BD Falcon, Franklin Lakes, NJ) with 5.0 µm pores 
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polycarbonate membrane. To perform invasion assay, 12-well cell culture inserts 
with 8.0 µm pores polyethylene terephthalate (PET) membrane were coated with 
100 µL 1μg/μl Matrigel (BD Biosciences, San Jose, CA, USA). Culture medium 
with 10% FBS was added in the bottom of the well as chemotactic stimulus. 
Following an overnight incubation, the top of the insert was cleared of cells (and 
Matrigel) with cotton swab; then, the top and the bottom of insert were washed 
3 times with 1X PSB. 
Inserts were incubated 30 minutes at room temperature with 11% glutaraldehyde 
to fix cells migrated on the bottom, and then washed 3 times with 1X PBS. After 
this, cells were stained with Crystal Violet and washed with 1X PBS. Cells from 
4 representative fields (10X and 4X magnification) from each insert were 
counted. 
 
Chromatin immunoprecipitation assay. 5x105 cells were fixed for 10 
minutes at room temperature with 1% (v/v) formaldehyde and crosslinking 
reaction was stopped with 125 mM glycine for 5 minutes at room temperature. 
Formaldehyde and glycine were removed by centrifugation (3 minutes at 13,000 
rpm). SDS and HBSS buffer were added to cells and DNA was sonicated using 
the Bioruptor® sonicator (Diagenode, Seraing, Belgium). 
Cellular debris were removed by centrifugation, then equal amounts of DNA 
were immunoprecipitated using anti-NF-κB-p65 antibody (Santa Cruz 
Biotecnology CA, USA) with anti-mouse IgG beads (Thermo Scientific, 
Waltham, MA, USA). 
Precipitated fragments were washed with dialysis buffer (2mM EDTA, 50mM 
Tris-Cl pH 8.00, 0.2% Sarkosyl), IP wash buffer (100mM Tris-Cl pH:9.0, 
500mM LiCl, 1% NP-40, 1% deoxycholic acid) and TE (1M Tris-HCl/ 0.1M 
EDTA) buffer. Fragments were eluted at 37 °C for 45 minutes with elution buffer 
(1% SDS, Sodium Bicarbonate 0.1 M) and, then, de-crosslinked with 5M NaCl  
at 65 °C overnight. Proteins were removed by samples using proteinase K and 
1M Tris-HCl/ 0.5M EDTA. After that, immunoprecipitated DNA was purified 
with QIAquick PCR Purification Kit according to the manufacturer’s 
instructions, and quantified by Real-Time PCR using specific primer sets 
flanking the expected p65 binding site: 
NF-κB-p65/HoxA5        Forward 5’-ACACACAGGTTTTCTCCCCA -3’ 
                                       Reverse 5’-GAATTTGATGGCGAGGGACC-3’ 
 
Statistical procedures. Data are expressed as means ± SD and means ± 
SEM of three independent experiments. Comparison between groups were 
performed using Student’s t-test. P values of less than 0.05 were considered 
statistically significant.  
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4. RESULTS 
 
4.1 Effect of MGO accumulation on angiogenesis in endothelial 
cells. 
 
Angiogenesis is a multistep process that generally begins in response to pro-
angiogenic stimulation when endothelial cells start to proliferate, migrate and 
invade the ECM to take part in the formation of an immature capillary structure 
and deposition of a new complex BM (Neve, Cantatore et al. 2014). 
It is known that increased MGO levels impair the endothelial function in various 
way and in different body district (Nigro, Leone et al. 2017), leading to 
development of micro- and macro-angiopathy associated to diabetes 
(Stehouwer, Lambert et al. 1997, De Caterina 2000, Schalkwijk and Stehouwer 
2005).  
In order to evaluate the MGO effect on angiogenesis, we have analyzed the 
angiogenic ability of endothelial cells isolated from the aortae of mice 
knockdown for the Glo1 gene (Glo1KD MAECs) and their wild type littermates 
(WT MAECs). 
To validate our model, we have analyzed the Glo1 mRNA levels in WT and 
Glo1KD MAECs by Real Time-PCR. In figure 15A, it is shown that Glo1 
mRNA levels are reduced by a 50% in Glo1KD MAECs compared to WT 
MAECs. This reduction is paralleled to a 5-fold increase of MGO intracellular 
concentration in Glo1KD MAECs compared to WT MAECs (figure 15B).  
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Figure 15. Glo1 gene expression and MGO intracellular concentration in Glo1KD and WT 
MAECs. A) Glo1 mRNA levels were assessed by Real Time-PCR in Glo1KD and WT MAECs. 
The bars in the graph represent the relative expression unit (REU) ± SD of three independent 
experiments. Experimental normalization was performed using Cyclophilin A gene as 
housekeeping control. B) MGO levels were measured by HPLC. Bars in the graph show MGO 
intracellular concentrations (nmol) normalized on milligrams of proteins. Statistical significance 
was evaluated using Student’s t test (*** p≤0.001).  
 
 
In order to test the angiogenic ability of these cells, we have evaluated their 
proliferation, migration and invasion ability. 
Glo1KD and WT MAECs cell growth was monitored up to 96 hours. Then, to 
test the invasion and migration ability, both Glo1KD and WT MAECs were 
seeded on the upper side of porous membrane transwell insert coated or not with 
Matrigel, respectively. FBS (10%) was used as pro-angiogenic stimulus. 
As shown in figure 16A, Glo1KD MAECs are characterized by a slower cell 
growth compared to WT MAECs. The proliferation, indicated as fold of cell 
number over time 0, is significantly reduced starting from 48 hours. Moreover, 
in response to 10% FBS, migration and invasion ability of WT MAECs is ⁓10-
fold and ⁓6-fold increased, respectively. Conversely, Glo1KD MAECs show a 
strong impairment of these ability in presence of 10% FBS (figure 16B, 16C).  
Together, these results indicate that MGO accumulation is responsible for an 
impairment of angiogenesis in Glo1KD MAECs. 
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Figure 16. Glo1KD and WT MAECs angiogenic phenotype. A) 5·104 MAECs were seeded 
in MW-6 plates and the proliferation was tested from time 0 to 96 hours by automated cell count 
of Glo1KD and WT MAECs. Proliferation in the graph is reported as fold of cell number over 
time 0. B) MAECs were seeded on the upper side of 5.0 µm polycarbonate membrane transwell 
inserts and the migration ability was tested in presence or not of 10% FBS by staining cells with 
crystal violet on the lower side of transwell insert. Migrated cells are visible in violet in the 4X 
magnification images on the left. The graph on the right represents the mean ± SEM of the fold 
increase of migrated cells in response to 10% FBS over the basal migration of cells in absence 
of 10% FBS. C) MAECs were seeded on the upper side of 8.0 µm PET membrane transwell 
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inserts coated with Matrigel and the invasion ability was tested as reported in figure legend 16B. 
Representative 10X magnification images are on the left of panel C. The graph on the right 
represents the mean ± SEM of the fold increase of migrated cells in response to 10% FBS over 
the basal migration of cells in absence of 10% FBS. Statistical significance was evaluated using 
Student’s t test (*p≤0.05, **p≤0.01, ***p≤0.001).  
 
 
 
4.2 HoxA5 involvement in MGO-mediated impairment of 
angiogenesis in MAECs. 
 
To identify the molecular mechanisms leading to the impaired angiogenesis in 
Glo1KD MAECs, we looked at candidate genes that are known to have a pivotal 
role in neovascularization. Among these, we analyzed the involvement of the 
antiangiogenic HoxA5 gene, that is the most representative Homeobox gene 
expressed in adulthood (Kachgal, Mace et al. 2012). 
Both protein (figure 17A) and mRNA (figure 17B) levels of HoxA5 are increased 
⁓2-fold in Glo1KD compared to WT MAECs. 
To demonstrate the involvement of HoxA5 in MGO-mediated angiogenesis 
impairment, HoxA5 expression was transiently silenced by the use of specific 
siRNAs. We used the transfection conditions leading to HoxA5 mRNA reduction 
in Glo1KD MAECs at similar levels to those of WT MAECs (data not shown). 
Interestingly, HoxA5 silencing results in the improvement of both migration 
(figure 17C) and invasion (figure 17D) ability of Glo1KD MAECs. 
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Figure 17. HoxA5 expression and its involvement in angiogenesis of Glo1KD and WT 
MAECs. A) Protein lysate were obtained by Glo1KD and WT MAECs and tested by western 
blot assay with anti-HoxA5 antibody. Anti-α-tubulin antibody was used as loading control. The 
bars in the graph represent the mean ± SD of the values obtained by the densitometric analysis 
of at least three independent experiments. B) HoxA5 mRNA expression was measured by Real 
Time-PCR. Cyclophilin A was used as housekeeping control gene. The bars in the graph 
represent the relative expression unit (REU) ± SD of three independent experiments. HoxA5-
siRNA was transfected in Glo1KD MAECs. Scramble siRNA was transfected as negative 
control. Bars in graphs show the fold increase of migration (C) and invasion (D) over the basal 
condition (w/o FBS). Statistical significance was evaluated using the Student’s t test (*p≤0.05, 
**p≤0.01).  
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4.3 NF-κB-p65 role in the regulation of MGO-mediated HoxA5 
overexpression. 
 
Evidence in literature indicates that exposure of ECs to hyperglycemia induces 
sustained activation of the transcription factor NF-κB, at least in part, by the 
AGEs/RAGE pathways (Nishikawa, Edelstein et al. 2000, Bierhaus, Schiekofer 
et al. 2001). 
Wondering how MGO may alter HoxA5 expression, we investigated the 
involvement of NF-κB-p65. 
To this aim, we evaluated NF-κB-p65 activation in Glo1KD and WT MAECs 
analyzing the translocation of p65 subunit into the nucleus. Cytoplasmic and 
nuclear proteins were fractionated and NF-κB-p65 levels were evaluated by 
western blot. Our results indicate that NF-κB-p65 is higher in both the cytosol 
and the nucleus (figure 18A) of Glo1KD MAECs compared to WT cells. 
In line with this, Glo1KD MAECs also show a ⁓2-fold increase of NF-κB-p65 
expression (figure 18B). 
Thus, these data demonstrate that a higher amount of activated NF-κB-p65 is 
present in ECs with high MGO levels. 
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Figure 18. NF-κB-p65 protein and mRNA levels in Glo1KD and WT MAECs. A) NF-κB-
p65 protein levels were evaluated on protein lysate from cytosol/nuclear fractionating by western 
blot with anti-NF-κB-p65 antibody. Cytoplasmic normalization was performed by using anti-
GAPDH antibody, and nuclear normalization with anti-CyclinG1 antibody. The bars in the graph 
represent the mean ± SD of the values obtained by the densitometric analysis of at least three 
independent experiments. B) NF-κB-p65 mRNA expression levels were measured by Real Time-
PCR. Cyclophilin A was used as housekeeping control gene. Statistical significance was 
evaluated using the Student’s t test (*p≤0.05, ***p≤0.001).  
 
 
Next, we performed a chromatin immunoprecipitation assay to test the binding 
of NF-κB-p65 to HoxA5 promoter.  
First of all, we looked for predicted p65 binding sites on HoxA5 promoter 
through the use of Jaspar software. The consensus sequence with the highest 
43 
 
score was amplified by Real Time-PCR, following the chromatin 
immunoprecipitation with a NF-κB-p65 specific antibody, to quantify the 
binding of NF-κB-p65 to the HoxA5 promoter.  
As shown in figure 19A, the binding of NF-κB-p65 to HoxA5 is higher in 
Glo1KD MAECs compared to WT MAECs. Interestingly, the inhibition of p65 
obtained by the use of JSH-23 is able to reduce the mRNA expression of HoxA5 
in Glo1KD MAECs (figure 19B).  
 
 
 
Figure 19. HoxA5 transcription regulation by NF-κB-p65 binding to its promoter. A) NF-
κB-p65 binding on HoxA5 promoter was tested by chromatin immunoprecipitation assay (ChIP) 
followed by quantization by Real Time-PCR of a putative high scored NF-κB-p65-consensus 
sequence on HoxA5 promoter. Bars in the graph represent a quantitation of the HoxA5 promoter 
region bound by NF-κB-p65 and are shown as the % of chromatin recovered by ChIP ± SD of 
three independent experiments. B) Cells were treated with 60 µM JSH-23 and HoxA5 mRNA 
levels were analyzed by Real Time-PCR. Cyclophilin A was used as housekeeping control gene. 
Statistical significance was evaluated using the Student’s t test (*p≤0.05, **p≤0.01).  
 
 
Taken together, these data demonstrate that MGO accumulation in Glo1KD 
MAECs is associated to a higher transcription and activation of NF-κB-p65 that, 
binding HoxA5 promoter, is able to positively regulate HoxA5 expression.  
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5. DISCUSSION 
 
T2DM is a chronic metabolic disease characterized by the presence of 
hyperglycemia. It is considered as an epidemic condition worldwide, nowadays 
without a cure (Dornadula, Elango et al. 2015). 
Over the years, hyperglycemia leads to the development of long-term micro- and 
macro-vascular complications. These complications are responsible of the high 
mortality associated to DM, affecting heart, blood vessels, eyes, kidney, nerves 
and wound healing process (Ribot, Caliaperoumal et al. 2016). 
Diabetic vascular disease is associated with impaired vascularization and/or 
aberrant angiogenesis. Indeed, an excessive angiogenesis is typical of diabetic 
retinopathy and nephropathy (Abu El-Asrar, Nawaz et al. 2013), while a reduced 
angiogenesis contributes to impaired wound healing and coronary collateral 
vessel development (Tahergorabi and Khazaei 2012). 
Giving the complexity of these alterations, although extensive research has been 
performed, the mechanisms underlying the abnormal angiogenesis occurring in 
diabetic patients are still not fully understood (Ribot, Caliaperoumal et al. 2016). 
Endothelial cell function is an essential requirement to guarantee a physiological 
angiogenesis (Kolluru, Bir et al. 2012). It is widely known that hyperglycemia 
induces endothelial dysfunction through the activation of several molecular 
pathways (Brownlee 2005). Among these, great attention has been paid to the 
increased formation of AGEs, playing a central role in the glucose-mediated 
vascular damage (Goh and Cooper 2008). 
In endothelial cells, one of the most important AGE precursor is MGO, a highly 
reactive dycarbonyl primarily formed by the intermediates of glycolysis (Baynes 
and Thorpe 1999, Thornalley 2005) and found to be increased from 2 to 5-fold 
in diabetic patients (McLellan, Thornalley et al. 1994). 
Emerging evidence have highlighted the harmful effect of MGO on endothelial 
function. We have previously demonstrated that treatment of both ECs in vitro 
and mice with non-toxic concentration of MGO impairs insulin sensitivity by 
changing the balance of NO and ET-1 release (Nigro, Raciti et al. 2014). 
Moreover, we have also recently found that MGO-induced down-regulation of 
miR-190a plays a role in this effect (Mirra, Nigro et al. 2017). 
In a study performed in rats, Berlanga et al. showed how MGO exposure leads 
to the impairment of wound healing and the development of diabetes-like 
vascular damage. In particular, MGO treatment is associated to the arrest of cell 
growth, hypercholesterolemia, impaired vasodilation and degenerative changes 
in cutaneous microvessels with loss of ECs (Berlanga, Cibrian et al. 2005). 
In physiological conditions, MGO is mainly detoxified by the glyoxalase system, 
of which Glo1 is the rate-limiting enzyme, representing the first line in the 
defense of cellular damage induced by the glycation process (Carmeliet 2005).  
It has been demonstrated that aging-dependent reduction of Glo1 delays wound 
healing in old mice (Fleming, Theilen et al. 2013); moreover, reduced Glo1 
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activity is associated with painful peripheral neuropathy in patients with T2DM 
(Skapare, Konrade et al. 2013). 
In line with this, the overexpression of Glo1 improves endothelial function and 
attenuates early renal impairment in a rat model of diabetes (Brouwers, Niessen 
et al. 2014). Moreover, Glo1 overexpression inhibits AGEs formation in bovine 
ECs (Shinohara, Thornalley et al. 1998) and improves hyperglycemia-induced 
impairment of angiogenesis in human microvascular ECs (Ahmed, Dobler et al. 
2008). 
Although several studies have demonstrated that high levels of MGO contribute 
to endothelial dysfunction and vascular complications, as indicated above, 
further investigations are still needed to clarify the underlying molecular 
mechanisms. 
Angiogenesis is a complex process highly regulated, in which new vessels are 
formed from pre-existing ones. In particular, this process involves endothelial 
cell proliferation, matrix degradation, cell migration, tube formation and vessel 
maturation (Carmeliet 2005). 
In the present study, we sought to investigate the MGO effect on angiogenesis 
and the underling molecular mechanisms, using an in vitro model of ECs 
characterized by endogenous MGO accumulation. 
In detail, ECs were isolated from aortae of mice knock-down for the Glo1 gene 
(Glo1KD MAECs) and their WT littermates (WT MAECs).   
The reduced expression of Glo1 in Glo1KD MAECs is paralleled to increased 
endogenous MGO levels. 
To evaluate whether and how the angiogenesis may be altered in these cells, we 
focused on their ability to perform the main steps of this process.  
Endothelial cell proliferation, migration and invasion are essential to 
angiogenesis. These motile processes are directionally regulated by several 
stimuli and involve the degradation of ECM to enable progression of migrating 
cells to form the new vessel (Lamalice, Le Boeuf et al. 2007). 
We here demonstrate that Glo1KD MAECs have an impaired angiogenic ability 
compared to WT cells. In particular, Glo1KD MAECs show a reduced 
proliferation. The observed impairment of cell growth seems to be not affected 
by cell apoptosis, but by a decrease in cell proliferation. Indeed, the cleavage of 
PARP, used as marker of apoptotic activation, was not revealed in Glo1KD nor 
in WT MAECs, differently from H2O2-treated MAECs (data not shown).  
Exposure to FBS (10%), used as pro-angiogenic stimulus, is able to induce 
migration of WT MAECs. Conversely, the migration ability is strongly impaired 
in Glo1KD cells in response to FBS. Furthermore, Glo1KD MAECs show an 
impairment of the ability to degrade an extracellular matrix extract and invade a 
porous membrane in response to FBS, differently from WT MAECs.  
In order to identify the molecular mechanisms leading to this phenotype, we 
focused our attention on the involvement of the anti-angiogenic HoxA5 gene. 
HoxA5 belongs to a family of highly conserved genes coding for transcription 
factors originally discovered for their role in the regulation of organ patterning 
during development (Murtha, Leckman et al. 1991). More recently, several 
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homeobox genes have been shown to affect physiological processes in adult 
tissues, including angiogenesis and wound healing (Kachgal, Mace et al. 2012).   
In particular, emerging evidence have highlighted the HoxA5 involvement on 
angiogenesis. Arderiu et al. demonstrated that sustained HoxA5 expression in 
murine hemangioma cell line (EOMA) reduces their growth in vivo (Arderiu, 
Cuevas et al. 2007). HoxA5 is also associated to retinoic acid-induced apoptosis 
and cell growth inhibition acting as a downstream mediator of retinoic acid 
receptor-β (Chen, Zhang et al. 2007). Furthermore, Cuevas et al. proved that 
sustained HoxA5 expression in murine ECs prevents angiogenesis by inhibiting 
the expression of the pro-angiogenic VEGFR2 and, at the same time, promoting 
the expression of anti-angiogenic TSP-2 (Cuevas, Layman et al. 2015).  
We also confirmed a reduction of VEGFR2 protein levels in Glo1KD MAECs 
compared to WT MAECs (data not shown). In line with this, Liu et al. show that, 
in bovine aortic endothelial cells (BAECs), MGO impairs endothelial 
angiogenesis through VEGFR2 protein degradation via a mechanism involving 
autophagy (Liu, Yu et al. 2012). 
These evidence support the idea that HoxA5 may represent a good target to look 
for answering the question of which mediator may be involved in the 
angiogenesis impairment observed in our model. 
Interstingly, Glo1KD MAECs show an increase of both protein and mRNA 
levels of HoxA5. This suggests that HoxA5 could be involved in the altered 
angiogenic phenotype found in Glo1KD cells. Thus, to validate this hypothesis, 
HoxA5 was transiently silenced in Glo1KD MAECs at similar levels of WT 
MAECs. 
Both migration and invasion ability of Glo1KD MAECs is improved by HoxA5 
silencing, highlighting HoxA5 as possible mediator of the harmful effect played 
by MGO on MAECs angiogenic function.  
Hyperglycemia-mediated vascular complications involve the activation of 
several biochemical cascades that have been largely investigated in the last 
decades, including pro-inflammatory pathways (Evans, Goldfine et al. 2002).  
In order to clarify how MGO could regulate HoxA5 expression we looked at the 
potential involvement of the pro-inflammatory transcription factor NF-κB. 
Activation of NF-κB has been suggested to contribute to the development of 
chronic disorders, such as diabetes and its associated complications. Indeed, 
Bierhaus et al. demonstrated that ligands of RAGE induce sustained activation 
of NF-κB in VSMCs, promoting the production of factors involved in the 
accelerated vascular disease (Bierhaus, Schiekofer et al. 2001). Furthermore, it 
has been recently demonstrated that MGO directly activates NF-κB translocation 
in synovial cells (Lin, Chan et al. 2016). 
In absence of stimuli, the heterodimer p65-p50 NF-κB is confined in the 
cytoplasm complexed with the inhibitory subunit, IκB. After stimulation, IκB is 
phosphorylated, marked for ubiquitination and then degraded. IκB degradation 
unmasks the nuclear localization signal (NLS) of NF-κB, allowing the 
translocation of p65 to the nucleus in order to induce the expression of several 
genes (Palombella, Rando et al. 1994).  
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In this study, we evaluated NF-κB-p65 protein levels after fractionating nuclear 
components from cytoplasmic protein lysate. Our data demonstrate that, NF-κB-
p65 protein levels are higher in both cytoplasmic and nuclear compartment of 
Glo1KD MAECs, compared to WT MAECs. Furthermore, also NF-κB-p65 
mRNA levels are overexpressed in Glo1KD MAECs. The increase of p65 in the 
nuclei of Glo1KD MAECs indicates that a major amount of this transcription 
factor is present in its active form in these cells compared to WT cells. 
To evaluate whether HoxA5 expression may be regulated by NF-κB, a search for 
a NF-κB-p65 consensus on murine HoxA5 promoter was performed by a 
bioinformatic software, following used to test the presence of a NF-κB-p65-
HoxA5 gene promoter binding by chromatin immunoprecipitation. This study 
allowed us to demonstrate for the first time that NF-κB-p65 binds HoxA5 
promoter in ECs and, interestingly, this binding is higher in Glo1KD MAECs 
compared to WT MAECs, suggesting that NF-κB-p65 overexpression may, in 
turn, mediate HoxA5 overexpression in Glo1KD MAECs. 
At this point, we sought to prove if this binding is functional to HoxA5 
expression. To this aim, one strategy has been to inhibit NF-κB activation using 
the aromatic diamine 4-Methyl-N 1-(3-phenyl-propyl)-benzene-1,2-diamine 
(JSH-23) that interferes with nuclear translocation, without affecting IκB 
degradation (Shin, Kim et al. 2004). 
In our hands, JSH-23 treatment is able to reduce NF-κB-p65 translocation into 
the nucleus of MAECs and this inhibition results in the reduction of HoxA5 
expression, indicating that the transcription factor NF-κB-p65 regulates the 
expression of the anti-angiogenic HoxA5 in MAECs. Ongoing experiments will 
further confirm this regulation by proving the concept that NF-κB regulates the 
expression of a reporter gene, via the identified promoter region of HoxA5, by 
the performance of luciferase assays. 
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6. CONCLUSIONS 
 
This study provides a novel mechanism in the understanding of the damaging 
effect of MGO on endothelium. Through the activation of the transcription factor 
NF-κB-p65, MGO accumulation induces the overexpression of the anti-
angiogenic HoxA5 gene which in turn impairs, at least in part, the angiogenic 
process in Glo1KD MAECs. 
Thus, this study highlights HoxA5 as a new mediator of the harmful effect played 
by MGO on angiogenic ability of endothelial cells. Further investigations will 
be useful in the identification of novel strategies for the prevention and treatment 
of diabetes associated microvascular complications. 
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Abstract: The highly reactive dicarbonyl methylglyoxal (MGO) is mainly formed as byproduct of
glycolysis. Therefore, high blood glucose levels determine increased MGO accumulation. Nonetheless,
MGO levels are also increased as consequence of the ineffective action of its main detoxification
pathway, the glyoxalase system, of which glyoxalase 1 (Glo1) is the rate-limiting enzyme. Indeed,
a physiological decrease of Glo1 transcription and activity occurs not only in chronic hyperglycaemia
but also with ageing, during which MGO accumulation occurs. MGO and its advanced glycated end
products (AGEs) are associated with age-related diseases including diabetes, vascular dysfunction
and neurodegeneration. Endothelial dysfunction is the first step in the initiation, progression and
clinical outcome of vascular complications, such as retinopathy, nephropathy, impaired wound
healing and macroangiopathy. Because of these considerations, studies have been centered on
understanding the molecular basis of endothelial dysfunction in diabetes, unveiling a central role
of MGO-Glo1 imbalance in the onset of vascular complications. This review focuses on the current
understanding of MGO accumulation and Glo1 activity in diabetes, and their contribution on the
impairment of endothelial function leading to diabetes-associated vascular damage.
Keywords: methylglyoxal; glyoxalase; vascular function; insulin-resistance
1. Introduction
Methylglyoxal (MGO) is a dicarbonyl aldehyde mainly formed as byproduct of glycolysis [1].
By its nature, MGO efficiently reacts with other molecules in the organism and causes cell and
tissue dysfunction [2]. While cells use glucose as major source of energy and store most of their
glucose in non-reactive molecules, as glycogen, a spontaneous and unavoidable leakage from
the Embden-Meyerhof pathway occurs in mammalian cells in the form of MGO [1]. It has been
estimated that about 0.1% of the glucotriose flux generates MGO by the non-enzymatic degradation of
glyceraldehyde 3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) [3]. Thus, glycolysis
contributes to the formation of MGO with a rate of about 125 µmol/kg cell mass per day under
normoglycaemic conditions [4]. This situation may be further increased under conditions that lead
to higher triosephosphate concentrations, like increased glucose metabolism in hyperglycaemia [5],
impairment of the pentose pathway decreasing GA3P disposal, or increased anaerobic glycolysis
occurring in hypoxia [6]. A minor amount of MGO is generated by acetone oxidation in the catabolism
of ketone bodies [7], aminoacetone oxidation in the catabolism of threonine [8], lipid peroxidation and
degradation of glycated proteins and monosaccharides [9,10].
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At variance, the contribution of exogenous sources is still controversial. Extremely high levels of
MGO were found in natural products, such as honey, and especially processed food and beverages like
soft drinks, coffee, and dairy products [11,12]. Indeed, MGO levels in foodstuffs is strongly affected by
heating [13], prolonged storage and fermentation, when microorganisms release MGO in alcoholic
drinks and cheese [11].Unexpectedly, variable levels of MGO can be found even in drinking water
that underwent treatments like ozonation and chlorination, which easily result in the formation of
MGO from humic substances [14]. It should be further considered that polluted air also represents an
exogenous source of MGO. In particular, smoking is a major source of indoor air contamination [15].
However, whether these exogenous sources of MGO are significant for plasma MGO levels has not been
clarified yet. Several studies report that free MGO is rapidly degraded during digestion in the intestine
and, thus, does not influence MGO level in vivo [16]. But there is also conflicting evidence indicating
brain and serum MGO accumulation in rodents fed MGO-supplemented diets and suggesting that at
least 10% of MGO-derived AGEs is absorbed and then accumulated in tissues like vessels, heart, liver,
kidney and adipose tissue [17,18].
MGO levels in healthy humans have been estimated to be about 50–150 nM in the plasma and
1–4 µM in tissues [19]. When the accumulation of MGO exceeds these levels, dicarbonyl stress occurs
as a consequence of the imbalance between the generation/exposure and MGO metabolism [20].
Under physiological conditions, >99% of MGO is detoxified by the glyoxalase system [21], with
minor metabolism by aldoketo reductases (AKRs) and aldehyde dehydrogenases (ADHs) which
convert MGO to hydroxyacetone and pyruvate, respectively [22]. The glyoxalase system consists of
glyoxalase 1 (Glo1), glyoxalase 2 (Glo2) and a catalytic amount of glutathione (GSH). Acting as the
rate-limiting enzyme, Glo1 catalyses the primary detoxification step by converting the spontaneously
formed MGO-GSH hemithioacetal to the thioester S-D-lactoylglutathione [23]. Its activity is directly
proportional to GSH concentration. Thus when cellular GSH concentration declines, as in oxidative
stress, Glo1 activity is impaired. Glo2 catalyses the hydrolysis of S-D-lactoylglutathione to D-lactate
and GSH [24]. With the exception of certain protozoa [25], both Glo1 and 2 are expressed in most
eukaryotes and prokaryotes [26,27], and are localized in the cytoplasmic compartment [28].
The modulation of Glo1 activity is dependent on both regulation of gene expression and
post-translational modifications. The Glo1 gene contains regulatory elements including ARE
(antioxidant-response element) in exone 1 [29], and its expression is negatively regulated by HIF1α
(hypoxia inducible factor 1α) binding to ARE under hypoxic conditions [30]. Indeed, hypoxia is an
important physiological driver of dicarbonyl stress as it facilitates MGO formation by increasing
metabolic flux through anaerobic glycolysis [6]. Hypoxia decreases Glo1 expression as well [3].
Furthermore, basal and inducible expression of Glo1 is subjected to stress-responsive control by
nuclear factor erythroid 2-related factor 2 (Nrf2) through regulatory AREs [29]. Current evidence
indicates that NF-κB constitutive activation in chronic hyperglycaemia, and related inflammation,
mediates the impairment in Glo1 expression and activity [31]. It has been further demonstrated that
NF-κB antagonizes the transcriptional activity of Nrf2 [32], suggesting that in a pro-inflammatory state,
typical of diabetes and obesity, NF-κB activation impairs Glo1 expression by inhibiting Nrf2 action.
Glo1 expression is also negatively regulated by the activation of the receptor of advanced glycated end
products (RAGE) and, again, NF-κB has an important role in this pathway [33].
While genetic polymorphisms of Glo2 are extremely rare, different SNPs (single nucleotide
polymorphisms) have been identified in the Glo1 gene and found to be associated with reduced enzyme
activity [34], increased prevalence of diabetic neuropathy [35], and increased risk of cardiovascular
complications [36]. Moreover, Glo1 is a hotspot for functional copy number variation (CNV) causing 2
to 4-fold increases in Glo1 expression in approximately 2% of the human population [37,38]. However,
further studies are needed to understand whether these patients are protected from MGO accumulation
and damage.
A physiological decrease of Glo1 activity and expression occurs with ageing, as demonstrated
by Morcos et al. in the nematode Caenorhabditis elegans, where an inverse correlation was found
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between ageing and Glo1 expression [39]. This same effect has been confirmed in rodents [40–42]. Glo1
expression is therefore likely linked to healthy ageing [43].
Thus, abnormal cellular accumulation of the dicarbonyl metabolite MGO occurs upon exposure to
high glucose concentrations, oxidative stress, inflammation, cell aging and senescence. It is associated
with increased MGO-adduct content of proteins susceptible to dicarbonyl modification, collectively
defined as dicarbonyl proteome [20], and with DNA instability and mutations [36,43]. An adequate
balance between MGO levels and Glo1 activity is necessary to ensure detoxification of MGO from
different sources and cell survival (Figure 1).
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Hyperglycaemia, oxidative stress, inflammation and exogenous sources of MGO contribute both to the
increase of MGO levels and the decrease of glyoxalase 1 (Glo1) activity. MGO-Glo1 imbalance leads
to vascular dysfunction contributing to endothelial insulin-resistance, hypertension, atherosclerosis,
microvascular complications, ageing and neuro-degeneration.
2. Effect of MGO Accumulation on Vascular Function
In the last decad s, an incr asing number of studies claiming a c ntral role for MGO in
vascular dysfu ction ha e been published [44]. Endoth lial dysfunct on is one of the major
factors in the development of cardiovascular disease. It has been recently reviewed how different
noxious agents induce endothelial dysfunction, promoting an amplified endoplasmic reticulum stress
response [45]. Vascular endothelium behaves as an autocrine and paracrine organ regulating vascular
homeostasis [46]. This is ensured by the tight control of the vascular tone, cell–cell interaction,
permeability and coagulation systems through the production of the extracellular matrix components,
and soluble factors in response to various stimuli.
When this bal ce is impaired, vasoconstriction may occur, along with l ukocyte adherence,
platelet activation, mitogenesis, pro-oxidation, thrombosis a d impaired coagulation, vascular
inflammation, nd therosclerosis [47]. Among the bioactive molecules generated by the endothelium,
nitric oxide (NO) plays a pivotal role in the maintenance of vascular homeostasis. NO controls vascular
tone by maintaining basal and induced vascular smooth muscle relaxation and opposing the action
of potent contraction factors, including Angiotensin II (Ang II) and Endothelin-1 (ET-1). In addition,
NO inhibits platelet activation and leukocyte adhesion and rolling, as well as cytokine-induced
expression of VCAM (vascular cell adhesion molecule) and MCP-1 (monocyte chemotactic protein-1),
thus promoting an anti-inflammatory action [47].
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MGO accumulation, perpetuated by Glo1 down-regulation, is linked to age-related diseases, such
as diabetes, obesity, disorders of the central nervous system and cardiovascular disease, which share
endothelial dysfunction as a common pathological denominator [47–50]. MGO reacts predominantly
with arginine residues on proteins, with methylglyoxal hydroimidazolone (MG-H1) being the most
prevalent MGO-derived AGE modification found in vivo, leading to structural change, inactivation
and degradation of target proteins [51]. Thus, increased levels of MGO impair endothelial function
in various way and in different districts in the organism. Several studies have shown an impairment
of endothelium-dependent vasorelaxation by MGO, mostly mediated by oxidative stress. Indeed,
acetylcholine-induced vasorelaxation is impaired in aortic tissue from rats by both high glucose and
MGO. This effect is attenuated by the MGO scavengers aminoguanidine (AG) and N-acetyl-cisteine
(NAC) [52], via the inhibition of NADPH oxidase [53], and is prevented by Glo1 over-expression [54].
A protective effect of anti-oxidants such as polyphenols has been reported to prevent MGO-dependent
impairment of NO release, improving endothelium-mediated relaxation in mouse corpora cavernosa [55].
A proposed mechanism by which MGO increases reactive oxygen species (ROS), promoting the
apoptotic process, involves the reduced transcription of the cytoprotective protein thioredoxin [56].
Moreover, accumulating evidence suggests that physiological angiogenesis is impaired by MGO
through RAGE-mediated and autophagy-induced vascular endothelial growth factor receptor 2
(VEGFR2) degradation [57]. Our preliminary data indicate that Glo1 down-regulation in mouse
aortic endothelial cells (MAECs) impairs the angiogenic process via a mechanism involving NFκB
(unpublished data).
A study performed in Goto-Kakizaki diabetic rats demonstrates that endothelial dysfunction is
worsened by MGO treatment, which increases oxidative stress, AGE formation and inflammation with
a decline in NO bioavailability [58]. Moreover, MGO accumulation in arterial walls causes vascular
contractile dysfunction in spontaneously hypertensive rats [59], and Dhar et al. have demonstrated
that MGO treatment activates NFκB through RAGE, thereby increasing renin-angiotensin levels and
blood pressure in Sprague-Dawley rats [60]. These findings provide further evidence that MGO is a
causative factor in the pathogenesis of atherosclerosis and development of macrovascular diabetic
complications. In humans, an association between MGO-derived AGEs and endothelial dysfunction
markers has been found in individuals with type 1 diabetes [61,62]. In addition, reduced Glo1 activity
in atherosclerotic lesions associates with increased HbA1c levels in non-diabetic patients [63].
As a pivotal mediator of endothelial-dependent release of NO and resulting smooth muscle
relaxation, endothelial nitric oxide synthase (eNOS) represents a target of the harmful effect of
MGO. Indeed, eNOS protein levels and its active phosphorylated form at the serine 1177 site are
decreased in long-term MGO treatment of rat isolated mesenteric artery [53] and in thoracic aortic
rings [64]. Also, eNOS uncoupling, found to be associated with O−2 generation and eNOS cofactor
biopterin depletion [65], contributes to redox-sensitive leukocyte recruitment and microvascular
leakage elicited by MGO [66]. In addition, age-related glycative and oxidative stress, resulting in
endothelial dysfunction, is reduced in Glo1 transgenic rats [67].
Besides macrovascular function, MGO and MGO-derived AGEs also play a harmful effect on
microvascular function, contributing to the onset of nephropathy and neuropathy. Indeed, regulation
of the Glo1 enzyme has been proved to be important in prevention of early renal impairment in
experimental diabetes [68], but also independently of hyperglycaemia in apoE−/− mice [69]. This is
also confirmed by the evidence that MGO accumulation in Wistar normal rats impairs several renal
disease markers progressively observed in diabetic Goto-Kakizaki rats [70]. MGO induces blood–brain
barrier damage by reducing the integrity and increasing the permeability of brain endothelial cells [71].
Recently, the generation of an occludin-MGO adduct, which leads to dysfunctional tight junctions
and increased brain microvascular endothelial cell (BMEC) permeability, has been identified as a
mechanism potentially involved in these abnormalities [72]. BMECs are crucial for brain vascular
repair and maintenance. Recent evidence obtained from both in vitro [73,74] and in vivo [75] models of
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brain ischemia demonstrates that MGO induces BMEC injuries and exaggerates ischemia-reperfusion
injury in diabetic rats.
Based on these findings, it became clearer that an effective reduction of MGO accumulation is
crucial for preserving vascular function. Several attempts to alleviate dicarbonyl stress have been made
in the last few decades, with MGO scavengers such as AG. But trials had to be terminated due to the
lack of efficacy, safety concerns or undesired side effects [18]. A promising strategy is the development
of Glo1 inducers through the activation and binding of Nrf2 to the Glo1 functional ARE. Up to now,
a Glo1 inducer combination of trans-resveratrol and hesperetin (tRES-HESP) has been evaluated in
a Phase 1 clinical trial and is now available for evaluation in Phase 2. In highly overweight subjects,
tRES-HESP improves arterial dilation and decreases the vascular inflammation marker VCAM-1 [76].
Further efforts in the development of pharmacological intervention to prevent dicarbonyl stress are
needed to provide new therapeutic options aimed at preventing vascular dysfunction in diabetes and
other age-related diseases.
3. MGO-Induced Insulin-Resistance: A Link to Endothelial Dysfunction
Because of its highly reactive nature, MGO rapidly binds protein residues, with arginine and
lysine representing the sites with the higher binding affinity [77]. This is particularly insidious as
arginine and lysine are amino acid residues with a high probability of being located in the functional
sites of proteins, including kinases involved in insulin signal transduction [3]. We and others have
provided evidence about the role of MGO on insulin-resistance in major target tissues for insulin action.
MGO interferes with insulin signaling in L6 skeletal muscle and beta cells. In INS-1E
beta cells it decreases insulin secretion through the inhibition of the insulin receptor substrate
(IRS)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway activation and
independently from reactive oxygen species production. The inhibitory effect of MGO and the
formation of AGE adducts on IRS are reversed by AG [78,79]. In addition, MGO administration
in vivo inhibits insulin secretion from isolated beta cells, due to decreased PDX-1 levels, and results in
higher levels of MGO-derived AGEs and insulin-resistance in muscle, liver, and adipose tissue [80–82].
Such effects are inhibited by the MGO scavenger Alagebrium, indicating the specificity of MGO
effects. In support of animal data and studies in animal models, a very recent human study in healthy
overweight individuals demonstrates that a diet with low AGE content decreases risk of type 2 diabetes
by improving insulin sensitivity [83]. Besides the canonical target tissue of insulin action, MGO induces
neuronal cell death in the central nervous system, and the impairment of insulin signaling was found
in astrocytes exposed to MGO [84]. In both mice and humans, dietary MGO and AGEs were positively
correlated with cognitive deficit, and inversely associated with the survival factor sirtuin-1 (SIRT1)
levels and other markers of insulin sensitivity, suggesting MGO dependent SIRT1 down-regulation as
a possible link between insulin-resistance and neurodegeneration [17].
Insulin also plays important haemodynamic actions. Insulin receptors were identified on endothelial
cells of both large and small blood vessels by Jialal and colleagues in 1985 [85]. The hemodynamic effect of
insulin was suggested by pivotal experiments reporting an insulin-mediated increase in blood flow
into leg skeletal muscle during a hyperinsulinemic euglycaemic clamp [86]. Indeed, insulin action
on endothelium is an integration of increased capillary recruitment and increased total blood flow.
Both of these effects are reduced and delayed in insulin-resistance [87].
At the molecular level, insulin binding to its cognate receptor on endothelial cells activates IRS,
PI3K and Akt, leading to the activation of eNOS [88]. eNOS catalyses the conversion of arginine
to citrulline and NO. Its activity is regulated by phosphorylation at multiple sites; two of the best
characterized sites are serine 1177 and threonine 495. Serine 1177 is rapidly phosphorylated by Akt in
response to insulin, whereas threonine 495 is constitutively phosphorylated in endothelial cells and
is thought to be a negative regulatory site [89,90]. Insulin is also able to cause rapid release of ET-1
via the mitogen-activated protein kinase (MAPK) cascade, which induces the activation of endothelin
converting enzyme (ECE) in endothelial cells [50], followed by vasoconstriction and proliferation
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of vascular smooth muscle cells (VSMCs). Studies enabling the understanding of the causal role of
insulin signal transduction in vasodilation were carried out in genetically modified animal models.
Mice lacking IRS-1 feature hypertension and impaired endothelium-dependent vasorelaxation [91].
Consistently, a polymorphism at arginine 972 IRS-1 is associated with decreased eNOS expression in
endothelial cells and plasma NO levels in human subjects [92]. Moreover, eNOS knock-out mice are
hypertensive and have a 40% lower insulin-stimulated glucose uptake than control mice [93], indicating
that insulin-mediated vasodilation and capillary recruitment are required for insulin delivery and
action at target tissues.
Besides the above mentioned harmful effect of MGO on insulin-sensitivity of insulin target
tissues, we have recently identified MGO as an endothelial insulin-resistance-inducing molecule
(Figure 2) [94]. Increased MGO levels are responsible for the impairment of insulin action in mouse
aortic endothelial cells (MAECs) exposed to exogenous MGO, or treated with the Glo1 inhibitor
S-p-bromobenzylglutathione cyclopentyl diester (SpBrBzGSHCp2), and in vivo in healthy mice chronically
treated with MGO. MGO exposure renders insulin unable to induce IRS-1 tyrosine phosphorylation,
its association to p85, Akt activation and the subsequent eNOS phosphorylation on serine 1177,
while the inhibitory phosphorylation of eNOS on threonine 497 is prevented by MGO accumulation.
eNOS inactivation results in loss of the insulin-dependent increase in NO production. Conversely,
ERK 1/2 activation is enhanced by MGO in both MAECs and aortic tissue from MGO-treated mice,
accompanied by increased phosphorylation of IRS-1 on its inhibitory site serine 616. The rescue of
IRS-1/Akt/eNOS pathway activation following the chemical inhibition of ERK 1/2 indicates that ERK
1/2 mediates, at least in part, the detrimental effect exerted by MGO on IRS-1/Akt pathway activation
by phosphorylating IRS-1 at serine 616. Furthermore, ERK 1/2 hyperactivation does not result in
increased MAEC proliferation, but rather in the increase of ET-1 production both in the absence and
presence of insulin, suggesting that MGO alters endothelial insulin signaling and causes an imbalance
between NO and ET-1 production, which facilitates vasoconstriction. Studies by Raoch et al. showed
that NO regulates endothelin converting enzyme 1 ECE-1 expression [95]. It is therefore possible that
the reduced NO levels also contribute to the activation of ECE-1 and the subsequent release of ET-1.
Int. J. Mol. Sci. 2017, 18, 188 6 of 14 
 
proliferation of vascular smooth muscle cells (VSMCs). Studies enabling the understanding of the 
causal role of insulin signal transduction in vasodilation were carried out in genetically modified 
animal models. Mice lacking IRS-1 feature hypertension and impaired endothelium-dependent 
vasorelaxation [91]. Consistently, a polymorphism at arginine 972 IRS-1 is associated with decreased 
eNOS expression in endothelial cells and plasma NO levels in human subjects [92]. Moreover, eNOS 
knock-out mice are hypertensive and have a 40% lower insulin-stimulated glucose uptake than 
control mice [93], indicating that insulin-mediated vasodilation and capillary recruitment are 
required for insulin delivery and action at target tissues. 
Besides the above mentioned harmful effect of MGO on insulin-sensitivity of insulin target 
tissues, we have recently identified MGO as an endothelial insulin-resistance-inducing molecule 
(Figure 2) [94]. Increased MGO levels are responsible for the impairment of insulin action in mouse 
aortic endothelial cells (MAECs) exposed to exogenous MGO, or treated with the Glo1 inhibitor 
S-p-bromobenzylglutathione cyclopentyl diester (SpBrBzGSHCp2), and in vivo in healthy mice 
chronically treated with MGO. MGO exposure renders insulin unable to induce IRS-1 tyrosine 
phosphorylation, its association to p85, Akt activation and the subsequent eNOS phosphorylation on 
serine 1177, while the inhibitory phosphorylation of eNOS on threonine 497 is prevented by MGO 
accumulation. eNOS inactivation results in loss of the insulin-dependent increase in NO production. 
Conversely, ERK 1/2 activation is enhanced by MGO in both MAECs and aortic tissue from 
MGO-treated mice, accompanied by increased phosphorylation of IRS-1 on its inhibitory site serine 
616. The rescue of IRS-1/Akt/eNOS pathway activation following the chemical inhibition of ERK 1/2 
indicates that ERK 1/2 mediates, at least in part, the detrimental effect exerted by MGO on IRS-1/Akt 
pathway activation by phosphorylating IRS-1 at serine 616. Furthermore, ERK 1/2 hyperactivation 
does not result in increased MAEC proliferation, but rather in the increase of ET-1 production both 
in the absence and presence of insulin, suggesting that MGO alters endothelial insulin signaling and 
causes an imbalance between NO and ET-1 production, which facilitates vasoconstriction. Studies 
by Raoch et al. showed that NO regulates endothelin converting enzyme 1 ECE-1 expression [95]. It 
is therefore possible that the reduced NO levels also contribute to the activation of ECE-1 and the 
subsequent release of ET-1. 
 
Figure 2. MGO-mediated endothelial insulin-resistance. MGO accumulation causes the reduction of 
miR-190a. Protein levels of miR-190a target KRAS increased, resulting in the hyperactivation of ERK 
1/2. The latter phosphorylates IRS-1 (insulin receptor substrate 1) on serine 616 inhibiting its 
activation and the downstream pathway PI3K/Akt/eNOS. These effects result in the impairment of 
insulin stimulated NO production by endothelial cells, together with increased ET-1 release. Red ↑: 
↓ ↓ ↓↓increased molecule levels; red : decreased molecule levels; blue : protein activation; blue : 
protein hyperactivation. KRAS (Kirsten rat sarcoma viral oncogene homolog). 
i r . - ediated endothelial insulin-resistance. MGO accumulation cau es th reduction
of miR-190a. Protein levels of miR-190a target KRAS increas d, resulting in the hyper ctivation of
ERK 1/2. Th latter sphorylates IRS-1 (insulin receptor subs rate 1) on serine 616 i ibiting
t at PI3 / eNOS. These e fects result i
l t r ction by endothelial ce ls, together with increased ET-1 release. Red ↑:
olecule levels; red ↓: decreased molecule levels; blue ↓: protein activation; blue ↓↓: protein
hyp ractivation. KRAS ( irsten rat arcoma viral oncogene h molog).
Int. J. Mol. Sci. 2017, 18, 188 7 of 14
Emerging evidence suggests that MGO may alter gene expression through miRNA regulation [96,97],
besides changes in DNA methylation [98] and histone modifications [99,100]. To answer the question
of how MGO increases ERK 1/2 activation in MAECs, we have carried on studies which led to the
recognition of miR-190a as an important modulator. The expression of this miRNA is down-regulated
in both MAECs treated with MGO and aortic tissue from mice where Glo1 expression has been knocked
down (Glo1-KD mice) [101]. The modulation of miR-190a inversely correlated with Kirsten rat sarcoma
viral oncogene homolog (KRAS) levels and ERK 1/2 activation. Furthermore, pretreatment of MAECs
with the inhibitor of class I and II histone deacetylase (HDAC), trichostatin A, was able to abolish
the MGO effect on miR-190a expression, suggesting HDAC involvement. Consistent with previous
findings proving the role of MGO in insulin-sensitivity and vascular function [53,55,78], the rescue
of miR-190a levels we observed in MAECs upon the co-treatment with MGO and AG, revealed that
MGO-modified proteins are critical in determining MGO-induced down-regulation of miR-190a.
Despite demonstration that MGO promotes insulin-resistance and hypertension by increasing
oxidative stress [81], other investigators reported MGO-mediated insulin-resistance in skeletal muscle
cells in the absence of ROS increases [79]. Whether oxidative stress may also play a part in
MGO-mediated endothelial insulin-resistance remains to be further addressed.
4. Mouse Models of MGO Accumulation
To study the impact of MGO on vascular function, animal models that allow observation of
the systemic implications of an imbalanced accumulation/detoxification ratio of MGO have been
investigated. Important insights in this field have been generated by studies carried out in rodents
that received MGO in drinking water [81], subcutaneous infusion with osmotic minipumps [80] or
by chronic intraperitoneal infusion [94,102]. However, exogenous sources of MGO are only partially
absorbed and not completely accumulated in tissues as free MGO, thus limiting the interpretation of
these studies. Indeed, MGO rapidly reacts generating in situ adducts that, depending on the nature
and half-life of the specific protein, can move in different ways to other districts in the organism
or remain confined to the site of administration [22]. Experimental studies have often used MGO
levels 10–20-fold higher than physiological concentrations. These conditions are similar to or exceed
the upper limit of severe dicarbonyl stress in poorly controlled diabetes [103]. Moreover, MGO is
physiologically formed intracellularly, as also indicated by the cellular MGO concentration exceeding
that in plasma of human subjects by 100-fold [104]. Measuring tissue and plasma levels in experimental
models is therefore necessary to ensure the patho-physiological relevance of the animal model.
A possibility to bypass these limitations is to modulate Glo1 activity and/or expression. Indeed,
reduced activity of Glo1, inducible by treatment with the chemical Glo1 inhibitor SpBrBzGSHCp2 or by
silencing Glo1 expression [105,106], mimics the physiological condition of endogenous accumulation
of MGO as a consequence of MGO/Glo1 imbalance, occurring in both diabetes and ageing [107].
Conversely, Glo1 over-expression reduces hyperglycaemia-induced carbonyl stress [108], and has
a protective effect on vascular dysfunction [68]. Chemical inhibition of Glo1 in apoE−/− mice is
able to increase endothelial inflammation and atherogenesis in the absence of hyperglycaemia, to a
similar extent as in hyperglycaemic mice with diabetes [109]. Other studies using Glo1 genetically
modified mice demonstrate its implication in microvascular complications. As reported by Giacco F.
and colleagues, modulation of Glo1 in mice influences the risk of nephropathy development [106].
Indeed, in non-diabetic mice, knockdown of Glo1 increases both MGO modification of glomerular
proteins and oxidative stress to diabetic levels, and causes alterations in kidney morphology which
are indistinguishable from those caused by diabetes. Conversely, in streptozotocin (STZ)-induced
diabetic mice, Glo1 over-expression prevents diabetes-induced increases in MGO modification of
glomerular proteins, increased oxidative stress, and the development of diabetic kidney pathology,
despite unchanged levels of diabetic hyperglycemia [106]. Recently, beneficial effects of Glo1
over-expression were also found in tubular cell survival, resulting in nephroprotective effects in renal
ischemia-perfusion injury [110]. Another study of Bierhaus A. et al., demonstrated that both chemical
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Glo1 inhibition in wild-type mice and non-diabetic Glo1 knockdown mice develop signs of peripheral
neuropathy, including thermal and mechanical hyperalgesia [105]. Strain dependent differences in
Glo1 copy numbers also confirm that a lower expression of Glo1 promotes the development of diabetic
neuropathy symptoms [111]. Very recent evidence obtained in Glo1 over-expressing mice has shown
that MGO increases inflammation in diabetes, leading to endothelial cell loss and, thus, contributing
to the development of diabetic cardiomyopathy [112]. Moreover, systemic Glo1 over-expression in
rats prevents age-related impairment of endothelium-dependent vasorelaxation through modulation
of eNOS phosphorylation, proving that blunting glycative stress prevents the long-term impact of
endothelial dysfunction on vascular ageing [67]. In line with these findings, our preliminary data
obtained in Glo1 knockdown mice indicated that Glo1 down-regulation is sufficient to increase blood
pressure with ageing, likely as a consequence of impaired endothelium-dependent vasorelaxation.
By contrast, previous studies in the same model did not reveal any differences in blood pressure
compared to wild-type mice [106]. In this study, however, blood pressure was recorded in young mice
where, even in presence of early signs of kidney damage, hypertension seemed to be not clinically
evident yet.
5. Conclusions
It is undeniable that MGO accumulation has harmful effects on vascular function, by inducing
insulin-resistance, hypertension, atherosclerosis, neurodegenerative disease and diabetic microvascular
complications. A large body of literature supports the concept that maintaining the MGO/Glo1
balance is crucial to guarantee the containment of MGO levels under the toxic threshold. To this
purpose, it is necessary to adopt a multi-task strategy. It is indeed not sufficient to minimize
MGO intake. Also, improving glucose control to treat vascular dysfunction is likely hampered
by metabolic memory. In this context, a promising contribution might be provided by modulating
Glo1 activity. At the moment, it is necessary to use optimal experimental models to further uncover the
pathways contributing to MGO accumulation and its effects, as well as its real impact on physiological
systems, fostering the development of novel and effective pharmacological interventions to prevent
vascular dysfunction.
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Methylglyoxal (MGO) is a reactive dicarbonyl produced as by-product of glycolysis, and its formation is height-
ened in hyperglycaemia. MGO plasma levels are two-fold to ﬁve-fold increased in diabetics and its accumulation
promotes the progression of vascular complications. Impairment of endothelium-derived nitric oxide represents
a common feature of endothelial dysfunction in diabetics.We previously demonstrated that MGO induces endo-
thelial insulin resistance. Increasing evidence shows that high glucose and MGO modify vascular expression of
several microRNAs (miRNAs), suggesting their potential role in the impairment of endothelial insulin sensitivity.
The aim of the study is to investigate whether miRNAs may be involved in MGO-induced endothelial insulin re-
sistance in endothelial cells.
MGO reduces the expression ofmiR-190a both inmouse aortic endothelial cells (MAECs) and in aortae frommice
knocked-down for glyoxalase-1. miR-190a inhibition impairs insulin sensitivity, whereas its overexpression pre-
vents theMGO-induced insulin resistance inMAECs.miR-190a levels are not affected by the inhibition of ERK1/2
phosphorylation. Conversely, ERK1/2 activation is sustained bymiR-190a inhibitor and theMGO-induced ERK1/2
hyper-activation is reduced by miR-190a mimic transfection. Similarly, protein levels of the upstream KRAS are
increased by both MGO and miR-190a inhibitor, and these levels are reduced by miR-190a mimic transfection.
Interestingly, silencing of KRAS is able to rescue the MGO-impaired activation of IRS1/Akt/eNOS pathway in re-
sponse to insulin.
In conclusion, miR-190a down-regulation plays a role inMGO-induced endothelial insulin resistance by increas-
ing KRAS. This study highlights miR-190a as new candidate for the identiﬁcation of strategies aiming at amelio-
rating vascular function in diabetes.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Methylglyoxal (MGO) is an endogenous dicarbonyl metabolite
formed mainly as by-product of the glycolitic pathway, from the
degradation of triose phosphates [1]. A minor contribution to its forma-
tion is also given by lipid peroxidation, threonine catabolism [2] and
non-enzymatic degradation of glucose and glycated proteins [3]. MGO
is a highly potent glycating agent, representing one of themost reactive
advanced glycated end product (AGE) precursor. It has been estimated
that 99.7% of MGO formed inside the cell is mostly metabolized by the
glyoxalase 1 (Glo1) enzyme [4]. In diabetic patients, the ﬂux of forma-
tion of MGO is increased two-fold to ﬁve-fold, depending on glycemic
control [5], and its accumulation may be heightened because of down-
regulation and increased degradation of Glo1 [1,6,7].
The increased formation ofMGO is one of themechanisms proposed
as the cause of insulin resistance [8–11] and important contributor to
the development of vascular complications in chronic hyperglycaemia
[12–15]. Indeed, studies in cellular and rodent experimental models
have demonstrated that high MGO exposure affects endothelial cell
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function including angiogenesis [16–19], contributes to inﬂammatory-
induced cardiomyopathy [20] and induces hypertension [21] and arteri-
olar atherogenicity by low density lipoprotein (LDL) glycation [22].
Impairment of endothelium-derived nitric oxide (NO) represents a
common feature of endothelial dysfunction in diabetic individuals
[23–25]. We have recently shown that MGO inhibits the insulin-
mediated activation of the phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (Akt)/endothelial NO synthase (eNOS) pathway, increases the
phosphorylation of Extracellular Signal-Regulated Kinase 1/2 (ERK 1/2),
and reduces NO release in mouse aortic endothelial cells (MAECs) [19].
However, the underlying molecular mechanisms remain to be further
investigated.
microRNAs (miRNAs) represent an evolutionarily well-conserved
class of small, non-coding RNAs that negatively regulate gene expres-
sion at the post-transcriptional level in a sequence-speciﬁc manner
[26]. Several studies have highlighted the role ofmiRNAs inmaintaining
the endothelial function and the impact of their alteration in endothelial
dysfunction [27,28]. Increasing evidence has demonstrated that miRNA
expression is affected by high glucose and MGO in vascular tissue and
this associates with the alteration of vascular reactivity [29–32]. In the
present study, we sought to investigate whether miRNAs may be in-
volved in endothelial insulin resistance induced by MGO in endothelial
cells.
2. Materials and methods
2.1. Reagents
Media, sera and antibiotics for cell culture were from Lonza
(Walkersville, MD, USA). MGO (40% in water), aminoguanidine bicar-
bonate salt (AG) and trichostatin A (TSA) were from Sigma-Aldrich (St
Louis, MO, USA). D-(+)-Glucose and D-(+)-Xylose were also from
Sigma-Aldrich (St Louis, MO, USA). U0126 was from ENZO Lifescience
(Florence, Italy). Insulinwas from Eli Lilly (Florence, Italy). The antibodies
used were anti-p-thr308-Akt, anti-p-tyr-IRS1 (Millipore, Billerica, MA,
USA), anti-p-ser616-IRS1 (Life Technologies, Carlsbad, CA, USA), anti-p-
tyr-IR, anti-Akt, anti-p-ser473-Akt, anti-eNOS, anti-p-ser1177-eNOS,
anti-p-thr497-eNOS (Cell Signaling Technology, Beverly, MA, USA), anti-
ERK1/2, anti-p-ERK1/2, anti-14-3-3 and anti-β-actin (Santa Cruz, CA,
USA), anti-KRAS (Abcam, Cambridge, UK) and anti-α-tubulin (Sigma-Al-
drich, St Louis, MO, USA). All other chemicals were from Sigma-Aldrich
(St Louis, MO, USA). Protein electrophoresis and western blot reagents
were from Bio-Rad (Richmond, VA, USA) and electrochemiluminescence
reagents from Pierce (Rockford, IL, USA).
2.2. Cell culture
Mouse aortic endothelial cells (MAECs) were kindly provided by T.H
Fleming (University of Heidelberg, Heidelberg, Germany). MAECs were
plated in T75 ﬂasks and grown in Dulbecco's Modiﬁed Medium
(DMEM) containing 1 g/l glucose supplemented with 10% (v/v) FBS,
2 mmol/l L-glutamine and 0.1 mmol/l non-essential amino acids. Cell
cultures were maintained at 37 °C in a humidiﬁed atmosphere contain-
ing 5% (v/v) CO2. Cells were starved in serum-free medium containing
0.25% (w/v) albumin bovine serum (BSA) for 16 h, treated with MGO
500 μmol/l and then exposed or not to 100 nmol/l insulin for 10 min.
Treatments with different concentrations of MGO for 16 h were also
performed in MAECs (Fig. S2a). AG 4 mM was used in presence of
MGO 500 μmol/l for 16 h. Where indicated, cells were pre-treated for
30 min with U0126 15 μmol/l and then treated with MGO 500 μmol/l
for 16 h. In addition, cells were pre-treated for 30 min with TSA
330 nmol/l and then treatedwithMGO 500 μmol/l for 16 h, where indi-
cated. Cells were exposed to 5 mM glucose (normal glucose control),
25 mM glucose (high glucose condition) or 5 mM glucose plus 20 mM
Xylose (osmotic control) for 24, 48 and 72 h.
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased
from the American Type Culture Collection (ATCC, Rockville, MD, USA)
and maintained in EGM-2 Bullet Kit from Lonza (Walkersville,
MD, USA). Cells were starved in serum-free medium containing 0.25%
(w/v) albumin bovine serum (BSA) for 16 h and treated with MGO
500 μmol/l.
2.3. Cell transfection
miR-190a levels were modulated by transfecting MAECs with miR-
190a-mimic (mmu-miR-190a-5p miRIDIAN Mimic) 0.5 nM or with
miR-190a-inhibitor (mmu-miR-190a-5p miRIDIAN Harpin Inhibitor)
5 nM using DharmaFECT 4 (Dharmacon, part of GE Healthcare,
Lafayette, CO). miRIDIAN microRNA Mimic negative control #1 and
miRIDIAN microRNA Harpin negative control #1 (Dharmacon) were
used as negative controls (scrambles) of miR-190a-mimic and miR-
190a-inhibitor transfection, respectively. After 48 h, the cells were di-
rectly harvested in the case of miR-190a-inhibitor or harvested after
MGO treatment, and analyzed as described below. KRAS protein levels
were reduced in MAECs transfected with a speciﬁc siRNA 50 nM or a
siRNA with a scrambled sequence used as a negative control, both of
which purchased from Integrated DNA Technologies (IDT, Coralville, IA,
USA). TransIT-TKO from Mirus Bio LLC (Madison, WI, USA) was used as
transfection reagent, according to the manufacturer's instructions.
2.4. Mice
Glo1-knockdown (Glo1-KD)micewere generated and characterized
as previously described [34,6,15]. Mice were housed in a temperature-
controlled (22 °C) room with a 12 h light/dark cycle, in accordance
with the Guide for the Care and Use of Laboratory Animals published
by the National Institutes of Health (publication no. 85-23, revised
1996), and experiments were approved by the ethics committee of
the MIUR. Reduced Glo1 mRNA levels were conﬁrmed by quantitative
PCR. For vascular insulin signaling, a bolus of insulin (0.15 U/g body
weight) was i.p. administrated to mice 10 min before they were killed
by cervical dislocation. Aortic tissueswere then collected and processed
as follow.
2.5. Western blot analysis
Cells andmouse aorta samples after homogenizationwere solubilised
in lysis buffer (50 mmol/l HEPES pH 7.5, 150 mmol/l NaCl, 10 mmol/l
EDTA, 10mmol/l Na2P2O7, 2mmol/l Na3VO4, 100mmol/l NaF, 10% glycer-
ol, 1% Triton X-100) for 2 h at 4 °C. Protein lysates were clariﬁed by
centrifugation at 16,000g for 20 min. Upon incubation with primary and
secondary antibodies (for a full list of the antibodies, see above), immuno-
reactive bands were detected by electrochemiluminescence according to
the manufacturer's instructions and densitometric analysis was per-
formed using ImageJ software.
2.6. Measurement of NO
NO was measured in cell culture medium. After treatments, culture
medium was collected, centrifuged at 1000g for 15 min and the super-
natant fraction was used as a sample solution for the detection, using
Nitrate/Nitrite Assay Kit Colorimetric (Sigma-aldrich). This assay uses
the Griess reaction, resulting in the formation of a chromophoric azo-
derivative, which absorbs light at 540–570 nm.
2.7. miRNA reverse transcription, miScript PCR Array and Real Time-PCR
Total RNA was isolated fromMAECs, HUVECs and mouse aorta sam-
ples after homogenization in Qiazol using miRNeasy mini kit (QIAGEN,
Hilden,Germany), according tomanufacturer's instructions. After quan-
tiﬁcation with NanoDrop 2000 spectrophotometer (Thermo Scientiﬁc,
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Waltham, MA), total RNA was reverse transcribed using the miScript II
RT Kit (QIAGEN) and analyzed by the Diabetes miRNA PCR Array
(QIAGEN; http://sabiosciences.com/mirna_pcr_product/HTML/MIMM-
115Z), according to the manufacturer's instructions. The PCR array was
provided in ready-to-use 96 well-plate, which contains 84 miRNA-
speciﬁc primers and different snoRNA/snRNA speciﬁc primers, used as
normalization controls. One plate was used for each experimental con-
dition. Resulting data were analyzed by the free data analysis software,
available at http://pcrdataanalysis.sabiosciences.com/mirna. The differen-
tial expression of miRNAs was then validated by Real Time-PCR using
themiScript SYBR Green PCR Kit (QIAGEN) and speciﬁc miScript Primer
Assays. The levels of all differential expressed miRNAs were quantiﬁed
as expression units relative to U6 snRNA, used as housekeeping small
RNA. Speciﬁc primers used for ampliﬁcation were purchased from
QIAGEN:
Mm_miR-190_3 miScript Primer Assay, MS00032438
Mm_miR-214_2 miScript Primer Assay, MS00032571
Mm_miR-34a_1 miScript Primer Assay, MS00001428
Mm_miR-126-5p_1 miScript Primer Assay, MS00006006
Mm_miR-129-3p_1 miScript Primer Assay, MS00006013
Mm_miR-199a-5p_1 miScript Primer Assay, MS00032529
Mm_miR-214_2 miScript Primer Assay, MS00032571
Mm_miR-320_3 miScript Primer Assay, MS00011767
Mm_miR-335_1 miScript Primer Assay, MS00002142
Mm_miR-375_2 miScript Primer Assay, MS00032774
Mm_miR-381_2 miScript Primer Assay, MS00032802
Mm_miR-450a_1 miScript Primer Assay, MS00025886
Mm_miR-451_1 miScript Primer Assay, MS00002408
RNU6B_13 miScript Primer Assay, MS00014000
2.8. Reverse transcription and Real Time-PCR
Reverse transcription of 1 μg of total RNA was performed using Su-
perScript III (Life Technologies, Carlsbad, CA, USA), according to the
manufacturer's instructions. Quantitative real-time PCR was performed
in triplicate by using iQ SYBR Green Supermix on iCycler Real-Time De-
tection System (Bio-Rad Laboratories, Hercules, CA, USA). Relative
quantiﬁcation of gene expression was calculated by the ΔΔCt method
(28). Each Ct value was ﬁrst normalized to the respective Cyclophilin
Ct value of a sample to account for variability in the concentration of
RNA and in the conversion efﬁciency of the RT reaction. Data were pre-
sented relative to the untreated control condition and reported as arbi-
trary units (REU). Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/) was used to design primers speciﬁc, which were then
purchased from Sigma-Aldrich (St Louis, MO, USA).
Primers used for real-time RealTime-PCR are as follow:
Cyclophilin Forward 5′-GCAGACAAAGTTCCAAAGACAG-3′
Reverse 5′-CACCCTGGCACATGAATCC-3′
Kras Forward 5’-CTCTAAGGGAGTGGGCTCCT-3′
Reverse 5′-GATCATTTGTGGATGCCGCC-3′
Tgfβ Forward 5’-ATACGCCTGAGTGGCTGTCT-3′
Reverse 5′-TGGGCCTGATCCCCTTGATT-3′
2.9. Statistic procedures
Data are expressed asmeans±SEMandmeans±SD, as indicated in
ﬁgure legends. Comparison between groups were performed using
Student's t-test or the one-way analysis of variance followed by Tukey
multiple comparison tests, as appropriate, using GraphPad Prism 6.01
software (GraphPad, San Diego, CA, USA): a p-value ≤ 0.05 was consid-
ered signiﬁcant.
3. Results
3.1. MGO exposure affects the expression of miR-190a in endothelial cells
The expression proﬁle of miRNAs experimentally identiﬁed and/or
bioinformatically predicted to be involved in diabetes-related biological
processes (see Materials and methods) has been evaluated by a miRNA
PCR Array in endothelial cells (MAECs) treatedwith 500 μmol/lMGO for
16 h [19]. Twelve out of 84 tested miRNAs resulted to be over or under
the arbitrary chosen cut-off (±log 0.5 fold changes vs untreated cells).
Among these, 5 miRNAs are up-regulated and 7 are down-regulated in
MGO treated MAECs compared to control untreated cells (Fig. 1).
The expression of these 12 miRNAs was then tested by Real Time-
PCR and the differential expression of miR-126, miR-190a, miR-214
and miR-450a was conﬁrmed. We then focused our attention on miR-
190a as its expression resulted to be the most signiﬁcantly reduced in
MGO-treated MAECs compared to control cells (Fig. 1).
Furthermore, the downregulation of miR-190a is also conﬁrmed in
human umbilical vein endothelial cells (HUVECs) exposed to 500 μmol/l
MGO(Fig. S1). Conversely, high glucose (up to72h)doesnot lead to a sig-
niﬁcant reduction of miR-190a (Fig. S2c).
As expected, the MGO scavenger AG is able to prevent the decrease
of miR-190a levels in MAECs treated with MGO (Fig. S2b), indicating
that the formation of MGO adducts is detrimental for miR-190a
expression.
3.2. The inhibition of miR-190a impairs insulin sensitivity in endothelial
cells
To establish whether miR-190a is involved in the MGO-induced
endothelial insulin resistance, its expression was antagonized by
transfecting the miR-190a inhibitor in MAECs (miR-190a inhibitor:
0.42 ± 0.16 vs scramble: 1.0 REU, p b 0.001). Similarly to MGO-
treated cells, the inhibition of miR-190a signiﬁcantly decreases the
insulin-induced tyrosine phosphorylation of IRS1 (Fig. 2a) and Akt
phosphorylation, both on ser473 and thr308 (Fig. 2b), compared to con-
trol MAECs transfected with a scramble miRNA, without affecting the
insulin-receptor (IR) phosphorylation (Fig. 2a). In addition, insulin-
dependent eNOS activation is impaired by the inhibition of miR-190a,
as shown by the reduction of phosphorylation on ser1177 and the loss
of de-phosphorylation on thr497 in response to insulin, compared to
scramble treated cells (Fig. 2c). Consistent with eNOS activation, insulin
stimulation induces a ~1.4 fold increase of NO release in scramble-
treated cells, as expected, while no increase of NO levels is revealed in
the culture medium from MAECs transfected with miR-190a inhibitor
(Fig. 2d). Furthermore, as in MGO-treated cells, the inhibition of miR-
190a increases basal ERK 1/2 phosphorylation (Fig. 2e). These data indi-
cate that, independently from MGO exposure, the reduction of miR-
190a levels is sufﬁcient to affect ERK 1/2 activation and insulin-
dependent IRS1/Akt/eNOS pathway in MAECs.
3.3. Overexpression of miR-190a prevents MGO-induced inhibition of insu-
lin sensitivity in endothelial cells
To investigate whether the reduced expression of miR-190a may be
crucial in mediating MGO effect on endothelial cells, miR-190a levels
were increased by transfecting cells with a miR-190amimic. As expect-
ed, insulin-induced IRS1, but not IR, phosphorylation (Fig. 3a), ser473
and thr308-Akt phosphorylation (Fig. 3b), and the downstream
ser1177-eNOS phosphorylation (Fig. 3c) are impaired in MAECs treated
with MGO. The over-expression of miR-190a in MGO-treated cells pre-
vents MGO deleterious effects, sustaining the insulin-mediated IRS1/
Akt/eNOS pathway activation even in presence of MGO (Fig. 3a–c). In-
terestingly, the over-expression of miR-190a also rescues the insulin-
induced NO release in MGO-treated MAECs (Fig. 3d). Moreover, the
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MGO-induced ERK 1/2 hyper-activation is prevented by transfection of
themiR-190amimic (Fig. 3e). These data indicate thatmiR-190a is a key
player in the MGO-dependent impairment of insulin sensitivity in
MAECs.
3.4. miR-190a down-regulation plays a role in MGO-induced endothelial
insulin resistance by increasing KRAS protein levels
MGO exposure affects insulin sensitivity in MAECs through the
hyper-activation of ERK 1/2 [19]. Thus, to establish whether ERK 1/2 ac-
tivation could be up- or down-stream the MGO-induced miR-190a
down-regulation, it was chemically inhibited. Pre-treatment with the
MAPK ERK Kinase (MEK) inhibitor U0126 prevents ERK 1/2 phosphory-
lation (data not shown) without affecting miR-190a expression
(Fig. 4a). Interestingly, the total protein levels of the GTPase Kirsten
Rat Sarcoma Viral Oncogene Homolog (KRAS), one of the validated tar-
gets of miR-190a [33], are increased by both MGO exposure and miR-
190a inhibitor transfection (Fig. 4b), and reduced when miR-190a ex-
pression is increased by miR-190a mimic transfection, even in presence
of MGO (Fig. 4c). Furthermore, the role of KRAS on MGO effect on
insulin signalling was evaluated in MAECs transfected with a speciﬁc
siRNA for KRAS. KRAS protein levels are reduced by siKRAS compared
to MGO-treated cells transfected with a scramble siRNA used as nega-
tive control (Fig. 4d). Silencing of KRAS prevents ERK 1/2 basal activa-
tion as well as IRS1 phosphorylation on ser616 (Fig. 4d), rescuing the
insulin-dependent Akt and eNOS activation (Fig. 4e). Taken together,
these data indicate that miR-190a down-regulation mediates MGO ef-
fect on endothelial insulin sensitivity, at least in part, by increasing the
levels of its target KRAS.
3.5. miR-190a and insulin sensitivity are reduced in aortae of Glo1-KDmice
To validate the effect of MGO on miR-190a in vivo, aortae were iso-
lated from non-diabetic Glo1-KD mice, described to have high levels
ofMGO-modiﬁed proteins (34; 15), andmiR-190a levels were analyzed
by Real Time-PCR. Vascular miR-190a expression is reduced in Glo1-KD
mice compared to their WT littermates (Fig. 5a). In aortae of WT mice,
insulin stimulation induces a 8- and 3-fold increase of ser473-Akt and
ser1177-eNOS phosphorylation, respectively. By contrast, aortae from
Glo1-KDmice show a 60% decrease of insulin-dependent Akt activation
and a 50% decrease of eNOS activation, compared to WT mice (Fig. 5b).
These data indicate that also in amousemodel that is prone to accumu-
late MGO-modiﬁed proteins (15), miR-190a and insulin sensitivity are
reduced in aortae.
3.6. Regulation of miR-190a expression by MGO
In order to address the mechanism bywhichMGOmay reducemiR-
190a levels, we started to look at the epigenetic regulation of miR-190a
[45]. Interestingly, the reduced expression ofmiR-190a is paralleled by a
consistent decrease of its host gene talin, suggesting that a possible
MGO-dependent modiﬁcation may occur at the level of talin promoter.
While the inhibitor of methyltransferases 5-azacytidine does not modi-
fy theMGO-inducedmiR-190a downregulation (data not shown), treat-
ment of MGO-exposed MAECs with the inhibitor of histone deacethyl-
transferases TSA is able to rescue the expression of both miR-190a and
talin gene at levels similar to untreated cells (Fig. 6a and b), suggesting
that miR-190a downregulation is potentially dependent by histone
modiﬁcations in presence of high MGO concentration.
4. Discussion
MGO is a highly reactive dicarbonyl compound, which is formed as a
by-product of glycolysis [1], and is a major cell-permeant precursor of
AGEs, reacting non-enzymatically with amino acid residues (e.g., Lys
and Arg) located in the active sites of proteins and thereby causing
their loss of function [35–37]. In condition of hyperglycemia, the plasma
levels of MGO are increased [5] and its abnormal accumulation contrib-
utes to the damage of various tissues in patients with diabetes [38,39],
also disturbing the insulin signaling pathway [8–11]. There is increasing
evidence that MGOmay contribute to the pathogenesis of insulin resis-
tance bymeans of direct functionalmodiﬁcations in themolecular com-
ponents of the insulin signalingpathway. For instance, an impairment in
the insulin-stimulated activation of IRS-1 has been observed in the adi-
pose tissue of fructose-fed rats and in 3T3-L1 adipocytes [40], in L6mus-
cle cells [11] and in INS-1E β-cells treated with MGO [9]. Moreover, in
our previous study, we proved that the exposure of both MAECs and
C57bl6 mice to MGO impairs the insulin-dependent IRS-1/Akt/eNOS
pathway and the consequent release of NO. In addition,we demonstrat-
ed that the MGO-dependent ERK 1/2 hyper-activation is responsible, at
least in part, for the negative effect of MGO on the IRS-1/Akt/eNOS sig-
naling pathway [19].
Emerging evidence suggests that MGO alters gene expression by
modifying transcription factors [41–43]. An interesting new concept
concerns the possibility that MGO may also affect gene expression
through changes in DNA methylation [44], histone modiﬁcations [45,
46] and miRNA expression [47,32]. Concerning the regulation of
miRNA levels, miR-30b was signiﬁcantly up-regulated in peritoneal
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Fig. 1.MGO effect onmiRNAs expression. The expression ofmiRNAs resulted to be differentially expressed in the PCR arraywas tested by Real Time-PCR inMAECs treatedwith 500 μmol/l
MGO. The bars in the graph represent the mean ± SD of the expression units relative to U6 snRNA levels, used as housekeeping gene. Control levels of miRNAs in not treated MAECs are
referred as 1 (dotted line). Statistical signiﬁcance was evaluated using the Student's t-test; ⁎p b 0.05, ⁎⁎⁎p b 0.001.
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mesothelial cells from MGO-injected rats [47]. In the A10 VSM line fol-
lowing MGO exposure, a signiﬁcant increase in the miR-9a-3p levels
was observed [32].
In line with these recent ﬁndings, we have examined here the in-
volvement of miRNAs as potential culprits behind the action of MGO
on the endothelium in order to explain the molecular mechanisms re-
sponsible for theMGO-dependent impairment of the endothelial insulin
sensitivity previously demonstrated [19]. Therefore, we have evaluated
the expression proﬁle of 84 diabetes-associated miRNAs through a
diabetic-speciﬁc array platform andwe have provided the ﬁrst evidence
thatMGOdown-regulates the expression ofmiR-190a inMAECs, aswell
as inHUVECs, and in aortae fromGlo1-KDmice. Furthermore, the aortae
of these mice showed an impaired insulin sensitivity compared to their
WT littermates. We performed the in vivo study in Glo1-KD mice
because they represent a suitable animal model to study MGO-
dependent effects, as in these mice the reduced levels of Glo1 are re-
sponsible for the accumulation of MGO-modiﬁed proteins and the de-
velopment of diabetic complications in the absence of hyperglycaemia
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[6,15,34]. The rescue of miR-190a levels observed in MAECs upon the
co-treatment with MGO and AG provided evidence that MGO-
modiﬁed proteins are critical in the down-regulation of miR-190a due
to MGO. We also observed that the exposure to chronic high glucose
caused a mild negative effect on the expression of miR-190a (Fig. S2c).
According to literature, miR-190a is differentially expressed in 3 tissues
related to glucose homeostasis, namely liver, adipose tissue and islets of
diabetic mice [48]. In lung adenocarcinoma A549 cells, miR-190a
inhibits the TGFβ (transforming growth factor-beta) signaling pathway
[49]. In addition, by repressing the expression of the PH domain leucine-
rich repeat protein phosphatase (PHLPP), a PH domain-containing ser-
ine phosphatase which speciﬁcally dephosphorylates and inactivates
Akt [50], increased levels of miR-190 are able to enhance the activation
of Akt in BEAS-2B cells [51].
In our cellmodel,we have observed that the over-expressionofmiR-
190a prevented the MGO-dependent inhibition of both the insulin-
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stimulated IRS-1/AKT/eNOS pathway and the NO release. The effect of
MGO on Akt seemed to be PHLPP-independent, as MGO showed no ef-
fect on the PHLPP protein levels in MAECs (data not shown). Further-
more, no effect on TGFβ was observed in the MGO-treated MAECs
(Fig. S3).Interestingly, the inhibition of miR-190a was sufﬁcient to
cause insulin resistance and impair the insulin-induced NO secretion,
thus mimicking the MGO-dependent effect on the insulin sensitivity
in the endothelial cells.
With the aim of establishing how MGO mediates the miR-190a
down-regulation in MAECs, we have investigated the ERK 1/2 pathway,
since: i. a decreased transcription of miR-190a has recently been
described to be dependent on ERK 1/2 nuclear activity in rat primary
hippocampal neuron cultures and in mouse hippocampi [52,53]; and
ii. the hyper-activation of ERK 1/2 mediates the MGO-dependent insulin
resistance in MAECs, as we have previously demonstrated [19]. In the
presence of U0126, a highly selective inhibitor of MEK kinases, MGO still
affected the miR-190a expression in MAECs, thus indicating that MGO
modulates the miR-190a expression independently of ERK 1/2 in the en-
dothelial cells. Conversely, when we induced alterations in the miR-190a
levels, an inverse correlation between the miR-190a and ERK 1/2 phos-
phorylation levels was observed, suggesting that the MGO-dependent
hyper-activation of ERK 1/2 might be mediated by miR-190a.
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To better clarify how miR-190a mediates the hyper-activation of
ERK 1/2, we initially tested whether alterations in the miR-190a levels
were able to modulate the expression of ERK 1/2. However, we did
not observe any difference in the protein levels of ERK 1/2 in MAECs
when alterations in the miR-190a levels were induced. Subsequently,
in accordance with the KEGG (Kyoto Encyclopedia of Genes and Ge-
nomes) pathway analysis [54], we identiﬁed the MAPK signaling path-
way as one of the most enriched molecular pathways in the miR-190a
target set, achieved through the combined results of 4 well-known
tools for miRNA target prediction (miRanda [55], Targetscan [56],
RNA22 [57] and miRWalk [58]). Among the 42 potential targets of
miR-190a related to the MAPK signaling pathway, we found KRAS, a
protein with an intrinsic GTPase activity which engages the canonical
RAF (Rapidly Accelerated Fibrosarcoma)/MEK/ERK as one of its down-
stream effectors [59]. For this reason, we tested the protein levels of
KRAS and we observed that alterations in the miR-190a levels were
able to modulate this target in MAECs. Consistent with our data, Hao
et al. have demonstrated by luciferase assays that KRAS is directly regu-
lated by miR-190a in HCT166 cells via a highly conserved binding site
[33]. In addition, the silencing of KRAS in our cell model prevented the
MGO effect on both the ERK 1/2 phosphorylation and the insulin-
stimulated IRS-1/PI3K/Akt/eNOS signaling pathway.
To address the mechanism by which MGO regulates miR-190a in
MAECs, as the miR-190a expression is associated with its host gene
talin [60], we investigated a possible involvement of the GC-rich region
with clusters of CpG dinucleotides in talin gene. No reversion of the
MGO effect on miR-190a levels was observed after the addition of
5-azacytidine, a pyrimidine nucleoside analogue of cytidine that in-
hibits DNA methyltransferase and impairs DNA methylation, thus
excluding the hypothesis of changes in DNA methylation for the
MGO-dependent down-regulation of miR-190a (data not shown). Con-
versely, TSA, which selectively inhibits the class I and IImammalian his-
tone deacetylase (HDAC), was able to abolish the MGO effect on the
miR-190a expression, suggesting thatHDACsmay be involved. In agree-
ment with our results, others have shown the increased interaction be-
tween O-Linked N-Acetylglucosamine (GlcNAc) Transferase (OGT) and
transcription factors modiﬁed by MGO, such as mSin3A [61], and the
consequent increased recruitment of HDACs in the complex of OGT
and the modiﬁed transcription factor to the promoter [62]. However,
the question of how MGO mediates the miR-190a down-regulation in
MAECs still remains unanswered and further experiments are necessary
to solve this issue.
5. Conclusion
This study shows for the ﬁrst time that MGO modulates miR-190a
levels and the miR-190a down-regulation contributes to the MGO-
dependent endothelial insulin resistance. Thus, in light of the
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observations that: i. a range of drugs, including the AGE inhibitor
aminoguanidine, have failed in clinical trials as a result of side effects or
limited efﬁcacy [63–66], and ii. alternative strategies to modulate the
AGE pathway, including approaches to reduce the accumulation of MGO
and enhance the Glo1 activity, are currently under investigation [67,68],
this study suggests miR-190a as a new player in the MGO-dependent
negative effect on the endothelial cell function, encouraging scientists to
address further efforts to prove that miR-190a may represent a novel
therapeutic target to ameliorate the endothelial insulin sensitivity in
diabetes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2016.11.018.
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Abstract
Aims/hypothesis Insulin exerts a direct action on vascular
cells, thereby affecting the outcome and progression of dia-
betic vascular complications. However, the mechanism
through which insulin signalling is impaired in the endotheli-
um of diabetic individuals remains unclear. In this work, we
have evaluated the role of the AGE precursor methylglyoxal
(MGO) in generating endothelial insulin resistance both in
cells and in animal models.
Methods Time course experiments were performed on mouse
aortic endothelial cells (MAECs) incubated with 500 μmol/l
MGO. The glyoxalase-1 inhibitor S-p-bromobenzylglutathione-
cyclopentyl-diester (SpBrBzGSHCp2) was used to increase the
endogenous levels of MGO. For the in vivo study, an MGO
solution was administrated i.p. to C57BL/6 mice for 7 weeks.
Results MGO prevented the insulin-dependent activation of
the IRS1/protein kinase Akt/endothelial nitric oxide synthase
(eNOS) pathway, thereby blunting nitric oxide (NO) produc-
tion, while extracellular signal-regulated kinase (ERK1/2)
activation and endothelin-1 (ET-1) release were increased by
MGO in MAECs. Similar results were obtained in MAECs
t r e a t e d w i t h SpB rBzGSHCp2 . I n MGO- a nd
SpBrBzGSHCp2-exposed cells, inhibition of ERK1/2 de-
creased IRS1 phosphorylation on S616 and rescued insulin-
dependent Akt activation and NO generation, indicating that
MGO inhibition of the IRS1/Akt/eNOS pathway is mediated,
at least in part, by ERK1/2. Chronic administration ofMGO to
C57BL/6 mice impaired whole-body insulin sensitivity and
induced endothelial insulin resistance.
Conclusions/interpretation MGO impairs the action of insu-
lin on the endothelium both in vitro and in vivo, at least in part
through an ERK1/2-mediated mechanism. These findings
may be instrumental in developing novel strategies for pre-
serving endothelial function in diabetes.
Keywords Endothelial dysfunction . Glyoxalase-1 . Insulin
resistance .Methylglyoxal . Nitric oxide
Abbreviations
ECE Endothelin-converting enzyme
ENOS Endothelial nitric oxide synthase
ERK Extracellular signal-regulated kinase
ET-1 Endothelin-1
Glo1 Glyoxalase-1
MAEC Mouse aortic endothelial cell
MAPK Mitogen-activated protein kinase
MGO Methylglyoxal
NO Nitric oxide
PI3K Phosphatidylinositol 3-kinase
SpBrBzGSHCp2 S-p-Bromobenzylglutathione-
cyclopentyl-diester
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Introduction
The decreased availability of endothelium-derived nitric oxide
(NO) accompanied by impaired endothelium-dependent va-
sorelaxation represents a common feature of endothelial dys-
function in diabetic individuals and is an important cause of
vascular disease [1]. Several studies have demonstrated im-
paired endothelium-dependent vasorelaxation in diabetic pa-
tients [2, 3] as well as in animal models of diabetes [4, 5]. In
addition to its effects on glucose metabolism, insulin has
important haemodynamic actions. Insulin acts on endotheli-
um, inducing the dilatation of arteries and arterioles by a
receptor-dependent mechanism which ac t iva tes
IRS1/phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial
nitric oxide synthase (eNOS) signalling leading to NO gener-
ation and vasodilation [6, 7]. Insulin is also able to cause rapid
release of endothelin-1 (ET-1) via the mitogen-activated pro-
tein kinase (MAPK) cascade and activation of endothelin-
converting enzyme (ECE) [8, 9]. Defects in insulin’s action
on endothelial cells may therefore lead to a shift in the balance
between the insulin-induced vasodilator NO and vasoconstric-
tor ET-1, with vasodilatation representing the normal response
and impaired vasodilatation, or even net vasoconstriction,
representing the abnormal responses associated with endothe-
lial dysfunction [10]. However, the mechanism(s) by which
insulin signalling becomes impaired in the vascular endothe-
lium of diabetic individuals remains poorly understood.
Hyperglycaemia, associated with impaired glucose toler-
ance and diabetes, causes insulin resistance and endothelial
dysfunction [11]. The entry of glucose into endothelial cells
occurs by facilitated diffusion and is insulin independent.
Increased blood glucose concentration will therefore lead to
increased intracellular accumulation of glucose and its asso-
ciatedmetabolites, making the endothelium highly susceptible
to hyperglycaemia-induced damage. Generation of AGEs has
an important role in the development of these abnormalities
and the accompanying vascular complications [12]. AGEs are
a heterogeneous family of non-enzymatically modified pro-
teins, the levels of which are increased in tissues and plasma
from patients with diabetes [13]. The highly reactive
dicarbonyl methylglyoxal (MGO) has been found to be the
most reactive AGE precursor in endothelial cells [14, 15].
MGO is an α-oxoaldehyde formed at a higher rate in
hyperglycaemic conditions by the fragmentation of
triosephosphates, the metabolism of ketone bodies or the
degradation of threonine [16]. MGO is detoxified to D-lactate
by the glyoxalase system, which consists of glyoxalase-1
(Glo1), glyoxalase-2 (Glo2) and a catalytic amount of gluta-
thione (GSH) [17]. Glo1 activity prevents the accumulation of
reactive dicarbonyls, such as MGO, thereby suppressing
dicarbonyl-mediated glycation reactions and is therefore a
key enzyme in anti-glycation defences [18, 19]. MGO reacts
non-enzymatically with the basic amino acids lysine and
arginine in proteins to formAGEs both extra- and intracellularly
[20]. Studies have demonstrated that increased MGO-derived
AGE levels in diabetic patients are associated with diabetic
vascular complications [21–23].
In this study, the effect of MGO on endothelial insulin
sensitivity was evaluated both in vitro and in vivo, and the
molecular mechanisms involved in the impairment of insulin
signalling and endothelium-dependent NO production
following exposure to MGO were investigated.
Methods
Reagents Media, sera and antibiotics for cell culture were
from Lonza (Walkersville, MD, USA). Protein electrophoresis
andwestern blot reagents were fromBio-Rad (Richmond, VA,
USA) and electrochemiluminescence reagents from Pierce
(Rockford, IL, USA). Protein-A sepharose and MGO (40%
in water) were from Sigma-Aldrich (St Louis, MO, USA).
Insulin was from Eli Lilly (Florence, Italy). The antibodies
used were anti-p-tyrosine, anti-Akt T308, anti-IRS-1
(Millipore, Billerica, MA, USA), anti-IRS1 S616 (Life Tech-
nologies, Carlsbad, CA, USA), anti-p85 (Upstate biotechnol-
ogy, Lake Placid, NY, USA), anti-Akt, anti-p-Akt S473, anti-
eNOS, anti-p-eNOS S1177, anti-p-eNOS T497, anti-14-3-3 ε
(Cell Signaling Technology, Beverly,MA, USA), anti-ERK1/2,
anti-p-ERK1/2 (Santa Cruz, CA, USA) and anti-α-tubulin
(Sigma-Aldrich). U0126 was from ENZO Lifescience
(Florence, Italy). PD98059 was from Sigma-Aldrich. The
inhibitor of glyoxalase 1, S-p-bromobenzylglutathione-
cyclopentyl-diester (SpBrBzGSHCp2), was kindly provided
by A. Bierhaus (University of Heidelberg, Heidelberg,
Germany). All other chemicals were from Sigma-Aldrich.
Cell culture procedure Mouse aortic endothelial cells
(MAECs) were plated in T75 flasks and grown in DMEM
containing 1 g/l glucose supplemented with 10% (vol./vol.)
FBS, 2 mmol/l L-glutamine and 0.1 mmol/l non-essential
amino acids. Cultures were maintained at 37°C in a humidi-
fied atmosphere containing 5% (vol./vol.) CO2. Cells were
starved in serum-free medium containing 0.25% (wt/vol.)
BSA, pre-treated (or not) with MGO 500 μmol/l for the
appropriate times, and then exposed (or not) to 100 nmol/l
insulin. Where indicated, cells were pre-treated for 30 min
with U0126 15 μmol/l or PD98059 30 μmol/l or for 48 h with
10 μmol/l SpBrBzGSHCp2.
Western blot analysis Cells were solubilised in lysis buffer
(50 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 10 mmol/l
EDTA, 10 mmol/l Na2P2O7, 2 mmol/l Na3VO4, 100 mmol/l
NaF, 10% glycerol, 1% Triton X-100, 1 mmol/l
phenylmethylsulfonylfluoride and 10 μg/ml aprotinin) for
2 h at 4°C. Cell lysates were clarified by centrifugation at
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16,000 g for 20 min. To analyse the phosphorylation of IRS-1
and its interaction with p85, 250 μg of protein lysates were
incubated with IRS-1 antibodies and then precipitated with
protein-A sepharose. Cell lysates or immunoprecipitated pro-
teins were then separated by SDS-PAGE and transferred onto
0.45 μm Immobilon-P membranes (Millipore). Upon incuba-
tion with primary and secondary antibodies, immunoreactive
bands were detected by electrochemiluminescence according
to the manufacturer’s instructions.
Measurement of NO NO was measured in cell culture medi-
um and mouse serum. After treatments, culture medium was
collected, centrifuged at 1,000 g for 15 min, and the superna-
tant fraction was used as a sample solution for the detection.
Serum was collected from the mice after cervical dislocation,
treated with Centricon 10 (Amicon, Beverly, MA, USA) at
4,000 g for 1 h at 4°C to remove haemoglobin and proteins.
NO concentration was detected by the use of Nitrate/nitrite
Assay Kit Colorimetric (Sigma-Aldrich). This assay uses the
Griess reaction, resulting in the formation of a chromophoric
azo-derivative, which absorbs light at 540–570 nm.
Measurement of ET-1 ET-1 was measured in cell culture
medium and mouse serum with a solid-phase sandwich
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Fig. 1 MGO impairs insulin signalling and NO release in endothelial
cells. MAECs were pre-treated (black bars) or not (white bars) with
500 μmol/l MGO for up to 16 h and stimulated or not with 100 nmol/l
insulin for 10 min. (a) Immunoblots of immunoprecipitated proteins (IP)
from whole-cell lysates. Immunoprecipitation was performed using the
anti-IRS-1 antibody as described in Methods. The blots (WB) were
probed with antibodies to p-tyrosine (p-Y), p85 and IRS-1. (b–d) Immu-
noblots of whole-cell lysates. The blots were probed with antibodies to
p-Akt S473, p-Akt T308 and Akt (b) and to p-eNOS S1177, p-eNOS
T497 and eNOS (c, d). Each bar graph represents the densitometric
quantification in three independent immunoblots. (e) NO release in the
culture medium. Values are expressed as fold over basal of triplicate
determinations. Statistical analysis was evaluated using Student’s t test;
*p<0.05, **p<0.01, ***p<0.001
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Fig. 2 MGO affects ERK1/2 and ET-1 release in endothelial cells.
MAECs were treated as reported in Fig. 1. (a) Immunoblots of whole-
cell lysates. The blots were probed with antibodies to p-ERK1/2 and
ERK1/2. To ensure accurate normalisation, the same blots were probed
with anti-14-3-3 antibody. Each bar graph represents the densitometric
quantification in three independent immunoblots. (b) ET-1 release in the
culture medium from these cells. Values are expressed as fold over basal
of triplicate determinations. Statistical analysis was evaluated
using Student’s t test; ***p<0.001
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ELISA (Immuno-Biological Laboratories, Hamburg,
Germany) according to the manufacturer’s instructions.
Animals and MGO administration Twelve-week-old
C57/BL6 male mice (n=30) were purchased from the Charles
River Laboratories (Milan, Italy). The mice were housed in a
temperature-controlled (22°C) room with a 12 h light/dark
cycle, in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (publication no. 85-23, revised 1996), and experiments
were approved by the ethics committee of the Federico II
University. MGO was administered i.p. over five consecutive
days each week for 7 consecutive weeks. The initial dose
administered was 50 mg/kg of body weight for the first
2 weeks, followed by a dose of 60 mg/kg for weeks 3 and 4
and a dose of 75 mg/kg for the last 3 weeks [24]. The same
protocol was performed twice in two different groups of mice.
Body weight was recorded weekly throughout the study. The
mice were divided into two groups and injected with MGO
solution (15 mice) or physiological solution (15 mice). After
7 weeks of treatment, mice from each group were killed by
cervical dislocation, the sera were collected and the aortas
were isolated and homogenised as previously reported [25].
Determination of MGO MGO inmouse serum samples or cell
extracts was determined by HPLC after derivatisation with
1,2-diamino-4,5-dimethoxybenezene as previously described
[26].
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insulin signalling and NO release
in endothelial cells. MAECs were
pre-treated (black bars) or not
(white bars) with 10 μmol/l of the
Glo1 inhibitor SpBrBzGSHCp2
(Glo1 Inhib) for 48 h and
stimulated or not with 100 nmol/l
insulin for 10 min. (a)
Immunoblots of
immunoprecipitated proteins (IP)
from whole-cell lysates.
Immunoprecipitation was
performed using the anti-IRS-1
antibody as described inMethods.
The blots were probed with
antibodies to p-Y, p85 and IRS-1.
(b, c, e) Immunoblots of
whole-cell lysates. The blots were
probed with antibodies to p-Akt
S473, p-Akt T308 and Akt (b), to
p-eNOS S1177, p-eNOS T497
and eNOS (c) and to p-ERK1/2
and ERK1/2 (e). Each bar graph
represents the densitometric
quantification in three
independent immunoblots. (d)
NO release in the culture medium.
Values are expressed as fold over
basal of triplicate determinations.
Statistical analysis was evaluated
using Student’s t test; **p<0.01,
***p<0.001
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Insulin tolerance test Mice were fasted for 4 h followed by
insulin injection (0.75 U/kg body weight, i.p.). Whole venous
blood was obtained from the tail vein at 0, 15, 30, 60, 90 and
120 min after the injection. Blood glucose was measured
using an automatic glucometer (One Touch Lifescan, Milan,
Italy).
Statistical procedures Data were analysed with Statview soft-
ware (Abacus Concepts Piscataway, NJ, USA) by one-factor
analysis of variance. A p value of less than 0.05 was consid-
ered statistically significant.
Results
MGO impairs PI3K-dependent pathway in endothelial
cells To determine whether MGO impairs insulin sensitivity
in endothelial cells, we pre-treated MAECs with 500 μmol/l
of MGO for up to 16 h and then stimulated the cells with
100 nmol/l insulin for 10 min. Pre-treatment of MAECs with
MGO suppressed insulin-induced IRS-1 tyrosine phosphory-
lation (Fig. 1a), as well as the interaction between the PI3K
regulatory subunit p85 and IRS-1 (Fig. 1a). The phosphory-
lation of the PI3K downstream target Akt at both T308 and
S473 sites, as well as its substrate glycogen synthase kinase 3
(ESM Fig. 1), was also suppressed by 16 h MGO treatment
(Fig. 1b). Pre-treatment with MGO for a shorter time period
(6 h) did not affect the insulin-induced Akt activation. Cell
viability was not affected by either the concentration of MGO
or the time used for cell exposure (ESM Fig. 2).
MGO impairs insulin-dependent NO production in endothelial
cells Insulin stimulation of MAECs resulted in a twofold
increase in the phoshorylation of S1177, the activation site
of eNOS (Fig. 1c), and a twofold decrease in phosphorylation
of T497, the inhibitory site (Fig. 1d). Pre-treatment withMGO
for 16 h suppressed insulin’s effect on the phosphorylation at
both of the eNOS sites (Fig. 1c, d), while pre-treatment with
MGO for 6 h did not affect the insulin-induced eNOS activa-
tion (Fig. 1c, d). Consistent with eNOS activation, the insulin-
induced NO release in the culture medium of MAECs was
suppressed by 16 hMGO pre-treatment (Fig. 1e). At variance,
insulin induced an increase in NO release of ∼40% in control
cells (Fig. 1e).
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Fig. 4 MGO-induced endothelial insulin resistance is mediated by
ERK1/2 basal activation. MAECs were pre-incubated with 15 μmol/l of
U0126 (light-grey bars) or with 30 μmol/l PD98059 (dark-grey bars) for
30 min. Cells were then treated or not with 500 μmol/l MGO for 16 h and
stimulated or not with 100 nmol/l insulin for 10 min. (a, c) Immunoblots
of whole-cell lysates. The blots were probed with antibodies to p-Akt
S473, p-Akt T308 and Akt (a) and to p-IRS-1S616 and IRS-1 (c). To
ensure accurate normalisation, the same blots were probed with anti-14-3-3
or anti-tubulin antibodies. Each bar graph represents the densitometric
quantification in three independent immunoblots. (b) NO release in the
culture medium from these cells. Values are expressed as fold over basal of
triplicate determinations. Statistical analysis was evaluated using
Student’s t test; **p<0.01, ***p<0.001
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MGO induces extracellular signal-regulated kinase 1/2
activation in endothelial cells Insulin stimulation resulted in
a twofold increase in the phosphorylation of extracellular
signal-regulated kinase (ERK) 1/2 in control MAECs and in
6 h pre-treatedMAECs (Fig. 2a). Pre-treatment withMGO for
16 h significantly increased both basal ERK1/2 phosphoryla-
tion and ET-1 release in the culture medium of MAEC cells
(Fig. 2a, b).
No further insulin-dependent increase in either ERK1/2
phosphorylation or ET-1 level occurred in cells exposed to
MGO for 16 h (Fig. 2a, b). At variance, insulin induced a 50%
increase of ET-1 release in control cells (Fig. 2b).
Glo1 inhibition impairs insulin signal transduction We then
aimed to increase the endogenous MGO levels by inhibiting
its detoxifying enzyme Glo1 [27]. Treatment of MAECs with
10 μmol/l of the Glo1 inhibitor SpBrBzGSHCp2 for 48 h
reduced insulin-induced IRS-1 tyrosine phosphorylation, as
well as IRS1/p85 interaction (Fig. 3a). Furthermore,
SpBrBzGSHCp2 caused a complete loss of insulin-induced
phosphorylation of Akt at both T308 and S473 sites (Fig. 3b)
and suppressed the effect of insulin on the phosphorylation of
eNOS at both S1177 and T497 sites (Fig. 3c). Impairment of
eNOS activation was accompanied by the loss of insulin-
dependent increase of NO production by the cells (Fig. 3d).
In contrast, in cells treated with the Glo1 inhibitor, ERK1/2
activation was increased in the basal condition compared with
control cells and its phosphorylation remained unchanged
after insulin stimulation (Fig. 3e). Thus, high levels of
MGO, whether induced by exogenous MGO exposure or by
inhibition of Glo1, reduce insulin sensitivity in endothelial
cells.
MGO-induced activation of ERK1/2 impairs insulin-
dependent Akt activation and NO production via IRS-1
phosphorylation on S616 Since ERK1/2 phosphorylates
IRS-1 on specific serine inhibitory sites [28, 29], we addressed
the issue of whether the activation of ERK1/2 induced by
either MGO or by Glo1 inhibitor could also have a role in
mediating its effect on the insulin-dependent IRS-1/PI3K/Akt/
eNOS pathway. Inhibition of ERK1/2 with both MEK inhib-
itors U0126 and PD98059 (ESM Fig. 3a, b) prevented
MGO-dependent suppression of insulin-induced effects on
the phosphorylation of Akt (Fig. 4a) and on NO release
(Fig. 4b). Furthermore, the effect of MGO on ET-1 release
was also prevented in cells treated with the MEK inhibitor
U0126 (ESM Fig. 3c). Interestingly, MGO increased IRS-1
phosphorylation on S616, and this increase was lost upon
MEK inhibition with both U0126 and PD98059 (Fig. 4c).
As shown in Fig. 5a, b, the inhibition of ERK1/2 by U0126
was also able to restore the Akt activation and NO release in
response to insulin, which were lost in MAECs treated with
SpBrBzGSHCp2. Moreover, as found for MGO-treated cells,
IRS-1 phosphory la t ion on S616 , inc reased by
SpBrBzGSHCp2 exposure, was abolished by U0126
(Fig. 5c). These data indicate that high levels of MGO impair
PI3K-dependent signal transduction, at least in part, via
ERK1/2-induced inhibition of IRS-1.
MGO administration causes insulin resistance in C57BL/6
mice To determine whether MGO affects insulin sensitivity
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Fig. 5 Glo1 inhibitor-induced endothelial insulin resistance is mediated
by ERK1/2 basal activation. MAECs were pre-incubated with 15 μmol/l
of U0126 (light-grey bars) for 30 min. Cells were then treated or not with
10 μmol/l of the Glo1 inhibitor SpBrBzGSHCp2 (Glo1 Inhib) for 48 h
and stimulated or not with 100 nmol/l insulin for 10 min. (a, c) Immu-
noblots of whole-cell lysates. The blots were probed with antibodies to p-
Akt S473 and Akt (a) and to p-IRS-1 S616 and IRS-1 (c). To ensure
accurate normalisation, the same blots were probed with anti-14-3-3 or
anti-tubulin antibodies. Each bar graph represents the densitometric
quantification in three independent immunoblots. (b) NO release in the
culture medium from these cells. Values are expressed as fold over basal
of triplicate determinations. Statistical analysis was evaluated using
Student’s t test; **p<0.01, ***p<0.001
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in vivo, C57BL/6 mice were treated with MGO for 7 weeks.
At the end of the treatment, MGO serum concentration was
increased by ∼2.6-fold in MGO-treated mice compared with
vehicle-treated mice (Table 1). Insulin tolerance tests showed
a significant increase in systemic insulin resistance in mice
treated with MGO compared with vehicle-treated mice
(Fig. 6a and Table 1). Western blots of the aortic tissue lysates
from MGO-treated mice showed a reduction of insulin-
induced activation of both Akt and eNOS (Fig. 6b, c). More-
over, insulin-stimulated NO release was completely lost in
MGO-treated mice compared with the control mice
(Fig. 6d). As previously observed in MAECs in vitro,
ERK1/2 activation and ET-1 release were increased at basal
level with no further significant increase upon insulin
stimulation in the aortic tissue and serum, respectively, from
MGO-treated mice compared with vehicle-treated mice
(Fig. 6e, f). Furthermore, MGO treatment increased IRS-1
phosphorylation on S616 in the aorta lysates (Fig. 6g). These
data indicate that in vivo MGO treatment impairs whole-body
insulin sensitivity and induces endothelial insulin resistance.
Discussion
Type 2 diabetes is an important risk factor for the development
of cardiovascular disease [1]. Several studies have highlighted
how insulin, besides its function as regulator of glucose ho-
meostasis, has important haemodynamic actions [30]. Alter-
ations in the endothelial insulin signalling pathway cause
endothelial dysfunction by modifying the balance between
ET-1 and NO production [31]. Hyperglycaemia itself plays
an important role in the onset and progression of vascular
dysfunction [32]. Awidely accepted hypothesis on the mech-
anisms implicated in glucose-mediated vascular damage in-
cludes the increased production of AGEs [12].
In the present study, MGO has been identified as an endo-
thelial insulin resistance-inducing molecule. It has been
shown that higher serum and adipose tissue MGO concentra-
tions are closely related to systemic insulin resistance [33].
Furthermore, it has been shown that MGO treatment in vitro
impairs insulin signalling activation in L6 skeletal muscle
cells [34] and glucose uptake in 3T3-L1 adipocytes [33].
However, the molecular mechanism(s) of MGO action on
insulin signalling in endothelial cells remains unclear.
In this study, we have shown that when endothelial cells are
pre-treated with a non-toxic concentration of MGO, insulin is
unable to induce IRS-1 tyrosine phosphorylation. The protein
level of IRS-1 was unchanged by MGO, suggesting that
alterations in the synthesis and/or degradation of IRS-1 are
not responsible for the impairment of its tyrosine phosphory-
lation. Consistent with the reduction in IRS-1 tyrosine phos-
phorylation, MGO treatment impaired the association of p85
with IRS-1, together with the activation of the downstream
PI3K effector, Akt. Insulin binding to its receptor on endothe-
lial cells also triggers the activation of the MAPK cascade,
which leads to the rapid release of ET-1 [32]. Despite the
impaired insulin-dependent induction of the IRS-1/Akt path-
way caused by MGO, ERK1/2 activity was enhanced by
MGO. MGO-induced ERK1/2 activation was accompanied
by increased phosphorylation of IRS-1 on its inhibitory site
Ser616. Interestingly, ERK1/2 inhibition by U0126 or
PD98059 resulted in both the reduction of IRS1 Ser616 phos-
phorylation and the rescue of insulin-dependent Akt activation
and NO production. Collectively, these findings indicate that
ERK1/2 mediates, at least in part, the detrimental effect
exerted by MGO on PI3K/Akt pathway activation by phos-
phorylating IRS-1 on Ser616.
Despite the constitutive activation of ERK1/2, we did not
observe any effects on MAEC proliferation (data not shown).
Indeed, in endothelial cells ERK1/2 modulates the interaction
between the ET-1 precursor (Big-ET-1) and ECE in the
Table 1 Metabolic characteristics of MGO-treated mice
Variable Before treatment After 7 weeks of treatment
Vehicle MGO Vehicle MGO
Body weight (g) 26.2±2.71 26.5±2.19 27.5±2.89 26.8±1.16
Food intake (g/day per mouse) 3.7±0.87 3.8±0.99 3.9±0.24 3.8±0.47
Fasting glucose (mmol/l) 5.3±1.0 5.4±1.0 4.9±0.6 5.2±1.0
Fed glucose (mmol/l) 9.3±1.6 9.1±1.9 9.3±1.9 9.2±1.8
ITTAUC (mmol/l × min) – – 6,344±1,621 9,814±3,537*
Serum MGO (nmol/l) – – 322±143 835±303***
Data are means ± SD of determinations in >10 mice per group
C57BL/6mice were injected i.p. with eitherMGO or physiological solution as control of vehicle injection. Bodyweight, food intake, fasting glucose and
fed blood glucose were monitored throughout the treatment period. At the end of treatment, serumMGOwas determined, an insulin tolerance test (ITT)
was performed on the two groups of mice and the AUCs are shown in the table
*p<0.01, ***p<0.001, MGO vs vehicle
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cytosol, resulting in ET-1 production [35]. Several studies
have reported that hyperglycaemia can induce glucotoxicity
by oxidative stress [12, 36], which is known to cause ERK1/2
activation [37]. It has been demonstrated that MGO induces
insulin resistance and salt sensitivity by increasing oxidative
stress in Sprague–Dawley rats [38]. However, MGO leads to
oxidative stress in a time- and dose-dependent manner; in-
deed, it has been found that MGO causes insulin resistance in
L6 cells at earlier times and at lower concentrations than those
necessary to induce oxidative stress [34]. Further studies will
be necessary to determine whether oxidative stress causes
ERK1/2 activation in MGO-exposed endothelial cells.
NO is a key molecule secreted by endothelium and acts as
the major mediator of insulin action on vascular homeostasis.
Impaired NO availability is pivotal in the development and
progression of vascular complications of diabetes. Indeed, it
has been shown that patients with either hypertension or
diabetes have relatively low NO plasma levels. Reduced NO
availability is of relevance to the development of atheroscle-
rotic complications in diabetes and to insulin-mediated post-
prandial glucose disposal and also contributes to the develop-
ment of insulin resistance [39]. eNOS catalyses the conversion
of arginine to citrulline and NO. Its activity is regulated by
phosphorylation at multiple sites, but two of the better-
characterised sites are Ser1177 and Thr495. Ser1177 is rapidly
phosphorylated by Akt in response to insulin, resulting in
increased eNOS activity and NO production, whereas Thr495
is constitutively phosphorylated in endothelial cells and is
thought to be a negative regulatory site, causing decreased
enzymatic activity [7, 40]. In the present study, it was shown
that MGO inhibits insulin-induced phosphorylation on eNOS
at Ser1177 and prevents the effect of insulin on the inhibitory
phosphorylation of Thr497. Furthermore, the reduced activa-
tion of eNOS is paralleled by the loss of insulin-dependent
increase in NO production. ET-1 production was also signif-
icantly increased inMGO-treated cells both in the absence and
presence of insulin. These results suggest that MGO impairs
insulin signalling thereby causing an imbalance between NO
and ET-1 production, which facilitates vasoconstriction. Re-
cent findings that NO regulates ECE-1 expression [41] sup-
port our results. It is therefore possible that the reduced NO
levels also contribute to the activation of ECE-1 and the
subsequent release of ET-1.
Estimates of the cellular and whole-blood concentrations of
MGO in healthy individuals are in the range of 1–5μmol/l and
120 nmol/l, respectively. The whole-blood MGO concentra-
tion is increased by five- to sixfold in patients with type 1
diabetes and by two- to threefold in patients with type 2
diabetes [17]. Therefore, the MGO concentration we used in
this study may not be considered of (patho)physiological
relevance. To overcome this issue, endogenous levels of
MGO were increased by inhibition of Glo1 with the cell-
permeable inhibitor SpBrBzGSHCp2. Previous studies report
a twofold increase in the intracellular concentration of MGO
in SpBrGSHCp2-treated HL60 cells [27]. Treatment of
MAECs with this inhibitor reduced the insulin-dependent
IRS-1 Tyr phosphorylation and its interaction with p85,
caused the complete loss of insulin-stimulated Akt
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Fig. 6 Effect of MGO administration on whole-body and endothelial
insulin sensitivity in mice. C57BL/6 mice were injected with MGO i.p.
(black squares, black bars), or with physiological solution (white squares,
white bars) as control vehicle injection. (a) MGO-treated and vehicle-
treated mice were subjected to insulin tolerance test. Values are expressed
as means ± SEM of determinations in >10 mice per group. (b–g) At the
end of treatment, five mice for each group were injected with insulin i.p.
(0.15 U/g body weight) 10 min before they were killed. Aortas were
isolated and the protein extracts were analysed by western blot. The blots
were probed with antibodies to p-Akt S473, Akt (b), p-eNOS S1177,
eNOS (c), p-ERK1/2, ERK1/2 (e), p-IRS-1 S616 and IRS-1 (g). Each bar
graph represents the mean ± SD of the densitometric quantification of the
blots obtained from at least three mice. (d, e) Serum NO (d) and ET-1
concentrations (f) in MGO-treated and control mice are expressed as
means ± SE for five mice in each group. Statistical significance was
evaluated using Student’s t test; *p<0.05; **p<0.01, ***p<0.001
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phosphorylation, eNOS activation and NO production and
also caused a significant increase of ERK1/2 activation in
the basal condition as compared with control cells, confirming
our previous finding with exogenous MGO.
The findings of this study provide further evidence that
increased MGO levels affect insulin sensitivity and insulin-
dependent NO production in vivo. Previous studies have
shown a positive correlation between MGO levels and insulin
resistance [34] as well as glucose intolerance in rats [40, 42].
Brouwers et al have shown that hyperglycaemia-induced im-
pairment of endothelium-dependent vasorelaxation is mediat-
ed by increased intracellular MGO levels [43], supporting the
need for further studies regarding the specific role of MGO in
endothelial function. In this study, it was found that healthy
mice chronically treated with MGO became insulin resistant.
Furthermore, IRS-1 phosphorylation on Ser616 was increased,
while insulin-induced Akt and eNOS activation were reduced,
in aortas from these mice. When compared with control mice,
MGO-treated mice also featured the loss of insulin-induced
increase in serum levels of NO. As found in vitro, this was
accompanied by increased ERK1/2 activation and ET-1 serum
levels, indicating that MGO is able to induce vascular insulin
resistance and endothelial dysfunction in vivo.
In conclusion, this work shows that increased concentra-
tion of MGO impairs the action of insulin on vascular endo-
thelium both in vitro and in vivo, leading to an imbalance
between NO and ET-1 production. Furthermore, we provide
evidence that ERK1/2 activation mediates, at least in part, this
effect in endothelial cells through the phosphorylation of IRS-1
on Ser616. Our findings highlight MGO as an important culprit
of endothelial dysfunction associated with insulin resistance,
providing new insights for the development of strategies to
preserve endothelial function in diabetic individuals.
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